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Abstract 
The objective of the study is to investigate the treatment methods of depression in public 
health care, and to conduct an analysis of the findings referring to a theoretical framework. A 
secondary objective was finding useful facts about the state of data recording, price 
formation, significance of outpatient care and others.  
The research first investigated possible and applicable approaches and metrics. Once they 
were chosen, they were described. The database of choice was the Ecomed system – a 
software package developed by Datawell Oy for the purpose of keeping patient records at 
HUS. The data was extracted from the database, evaluated and an empirical analysis was 
conducted. The empirical data consisted of an excel worksheet containing non-personal 
information of patient visits, costs, dates, places and other variables.  
The research showed that there are distinct patterns in treatment methodologies in terms of the 
duration of treatment. There are patient groups with treatment durations of 0 days, of up to 30 
days, of up to 90 days, of up to 350 days, and of up to 1100 days. The mainly qualitative 
results show a degree of coherence with the theoretical framework. In addition, practicalfacts 
about price formation, frequencies of visits and others were shown (useful to the organization, 
not to the main aim of the study). The study paves way for progress in implementation of 
modernization projects at the organization.  
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Introduction 
The recent economic downturn has made numerous companies rethink their ways of doing 
things. It has revealed inefficient methods and the resulting poor performance. Although 
public organizations has incentives other than maximising profits and shareholder value, 
many of them are now looking at ways to improve their efficiency as well. The mental health 
treatment at the Hospital District of Helsinki and Uusimaa (Helsingin ja Uudenmaan 
Sairaanhoitopiiri – HUS) has been moving in the direction of quantitative analysis and 
improvement of efficiency for a number of years, but it is now facing increasing pressure to 
renew its organizational structure and the processes within. As a public organization with a 
strong political backing of general health coverage, it has battled the stale state of corporate 
culture – things are done today as they were first done decades ago. Society is evolving, the 
economy is pressing and the patient queues are growing. Re-engineering projects are being 
launched throughout HUS to face these new challenges and improve efficiency through 
renewed practices. 
 
Motivation for the study 
Several departments at HUS have implemented process thinking in their treatment which has 
helped them improve efficiency by means of motivation for shorter treatment periods, 
standardized procedures and simpler billing. A tool that has supported this philosophy is 
called the diagnosis-related group (DRG) method. In essence, the DRG system is a pricing 
scale for any treatment services provided. A bill is made according based on a standardized 
treatment package. To develop this scale, the work hours involved, the equipment and the 
facilities used must be considered. An average is then taken and the patient is billed 
accordingly. Although DRG has been successful in the somatic departments of HUS 
psychiatry was left out of the implementation back in the early 90‟s.  
Now, with the new administration and the increased pressure brought about by the economic 
downturn the psychiatric department is looking into the system and the philosophy once more. 
Despite the fact that there have been studies suggesting that DRG is difficult to implement in 
psychiatry, the temptation of higher efficiency that the somatic department have shown is too 
great to overlook. 
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For the system to yield the desired effect of shorter treatment periods, it has to be 
standardized. If the required treatment is shorter than average, the standard price is still 
charged. If the required treatment is longer than average, it is still priced at the standard fee. 
This way keeping patients for too long would result in free (and probably unnecessary) 
treatment, which should be avoided to increase the efficiency.  
This raises the question of defining the standard treatment. How important is it to commence 
treatment early? Who conducts the preliminary evaluation? What procedures should be 
conducted? What medication should be used? How frequent should the visits be? For a knee 
operation, the standard is simple: lab tests, an operation, a cast for several weeks, pain 
medication, crotches rental, physiotherapy. For a mental disorder a standard would appear to 
be more complex – and it truly is. 
However, certain standards do exist. They are defined in the Current Care Guidelines (CCG, 
Käypä Hoito –suositukset). These guidelines are made by work groups of the Finnish Medical 
Society Duodecim, and they specify a number of treatment standards based on sound medical 
research (this study takes CCG as the medically correct way of treating the disorder in 
question). The number of options for treatment depends on the nature of the condition of the 
patient, and the conditions in psychiatry are often multidimensional and unique (this 
complexity is a chief argument against DRG in psychiatry). This study uses depression as the 
sample data as the treatment is somewhat standardised and uniform. Moreover, this sample is 
a significant portion of the total number of patient visits at HUS (approx. 25%) giving an 
abundance of data and making the results applicable as standalones, not just as samples of the 
total. 
Unfortunately CCG‟s are merely guidelines. Despite the fact that they are made by leading 
professionals, they are rarely followed or enforced. In addition, they do not explicitly define 
the timing, the desired level of morbidity, nor the responsibility for the tasks involved. Today, 
it appears that every treatment procedure is assessed and altered individually by the treating 
personnel as it goes on. This sometimes results in patients‟ treatment lasting for years, which 
is virtually useless as suggested by the CCG. 
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Methodology of the study 
There have been very few formal studies done in these organisations but the general attitude 
seems to be that the CCG‟s are just theoretical and are not meant to be followed. This study 
attempts to model the CCG‟s in terms of processes and hence identify the extent to whic h 
they actually are followed, and what are the implications and the possibilities of their use or 
the lack of it. The data used in this study is gathered from a system called Ecomed. This is a 
vast database of patient visits for all of HUS. Each line of data contains upwards of 170 
entries including patient ID, diagnosis, date of visit type of visit, severity of symptoms and 
many others. The first task in the data analysis is an evaluation of the quality of the data both 
in terms of the structure of the system and in terms of how well it is filled out. First 
impressions suggest that the quality of the data is far from perfect. The second task is to draw 
out patterns and standards in the data. Considering the general opinion of several employees, 
tremendous variability in the treatment periods is expected. The extent of them is then 
measured and reported. The third task is to compare these findings to the ideal processes 
suggested by the CCG. 
The analysis reveals the level of similarity between the CCG and the reality, and draws out 
implications of any disparity. The report includes figures of work hours and of costs involved. 
It is expected, that the CCG‟s are not thoroughly followed, but if they were, the costs and the 
treatment periods would be dramatically reduced which would lead to a greater turnover of 
patients and therefore “more mental health generated”.  
Implementing process thinking and DRG in psychiatry is another question altogether. First of 
all, the level of possible standardization in other samples might be (and apparently is) very 
different. This effectively eliminates the applicability of DRG in those fields (although some 
research suggests that process thinking can be employed even in schizophrenia – a field with 
enormous differences in treatment methods). Despite this, since depression is such a major 
part HUS, these results might assist the implementation of DRG at least in that field. 
Improving efficiency in a single field (especially in one as big as this one) would be a 
remarkable achievement. 
There will also be significant political challenges in the implementation of this new 
philosophy. Psychiatry has traditionally been a field where human interaction and patient-
doctor relationships have been considered paramount. Suggesting that treatment could and 
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should be standardized would likely provoke critique. The study will give the administration 
of HUS a considerable advantage when attempting to implement these reforms.  
In addition to assisting the implementation, the study will also be a valuable contribution for 
any further scientific research in this grand project. Most notably, there is a possibility of 
extending these results into measures of the efficiency of different treatment methods. A study 
like this would require an analysis of mental health factors such as ability to work, number of 
early pensions or the ability to create personal relationships. A study like that however would 
require permissions from KELA (the social insurance institution of Finland) which are known 
to take several months to process. Given the usual depth of a master‟s thesis, a major study 
that could link processes to the efficiency of psychiatric treatment should be conducted on a 
separate occasion. 
This paper is divided into 5 major chapters. The first chapter covers the structure and the 
current challenges faced by the organization. The second chapter introduces the concepts and 
definitions related to measuring depression and mental health care in general. The third 
chapters deals with the process, the challenges and the quality of the data used in the study. 
The fourth chapter analyzes the data and draws out some relevant conclusions. Finally, the 
findings and implications are summarized in the fifth chapter.  
 
Goal of the study 
The aim of this study is thus to identify patterns in treatment methods in the treatment of 
depression at HUS, and to assess those findings in terms of the existing guidelines. These 
results would lay a basis for further research that could lead to the ultimate implementation of 
product packaging at HUS. 
 A medically sound guideline for treatment does exist and it specifies an optimal treatment 
path for a strictly specified group of patients. Treatment past that optimum timeline, and of 
patient groups not requiring the specialized (and expensive) care is redundant and hence 
inefficient. Employees must therefore be encouraged not to keep treating the patients after this 
moment, but sign them out of the system. The patients – whether cured or not (but given the 
appropriate treatment) – are then to be transferred to another authority, namely one in primary 
healthcare. This requires motivation by the employees to obey the guidelines and strive for 
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standards. Whether motivational tools should be implemented, a baseline of the current 
situation must be measured. 
The measures that the guidelines considered in this study define include: duration of 
treatment, frequency of visits, morbidity, prescribed medicine, treatment methods (therapy, 
medicine, ECT). Of those, the duration of treatment, the frequency of visits and possibly 
treatment methods can be identified in this study. The other metrics are either poorly recorded 
or they are contained in a different database altogether. The available figures are then to be 
compared with the costs (also found in the data), and correlations and patterns are to be 
identified. After that, a theoretical situation where the guidelines are always followed is to be 
defined, and the difference compared to the real situation.  
As said, this is one of the first steps in a grand re-engineering project that is now to be 
undertaken in HUS psychiatry. Since this is a formal quantitative study, the findings of this 
study can then be used as justification for reforms, as hard statistics-based facts that cannot be 
shot down with “oh, what do you know”. There are numerous other challenges that lie ahead 
for the management team, including implementations of new motivational tools and changing 
the organizational culture. This study is to assist these future solutions by giving a baseline of 
the current situation with solid statistical data, and thus help achieve the goal of higher 
efficiency. 
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Overview and challenges of current situation 
This chapter gives an overview of the organization at hand, the problems it is facing, and 
hence the motivation and the necessity of this study. The overview of the situation and the 
challenges is based on web sites and a number of interviews conducted with several senior 
managers and specialists in HUS. First, the grand picture of how the organization is structured 
is presented. Then an overview of the major challenges is given. Finally the goals of this 
study are summarized considering the major problems described first.  
 
Structure of the organization and sample 
The structure of the organization has a number of levels and this subchapter gives a general 
overview of them. The top level is hospital districts, the next is hospital areas, then hospitals 
or specialties. Of the hospital levels, HUS is of interest for this study. Within HUS, the 
section in question is psychiatry. Further, the sample selected is care of depression in Jorvi 
and Peijas hospitals. Lastly, this subchapter describes the managerial set up of HUS.  
 
Psychiatry at Hospital District of Helsinki and Uusimaa – HUS 
There are two major levels of medical care Finland – primary health care and secondary 
health care. Primary health care is the basic treatment that can be received in general health 
clinics (Terveyskeskus), whereas secondary health care is given by medical staff specialized 
in a given field. Secondary health care is available in hospitals, clinics or university hospitals. 
This general division, and the organization considered in this study, can be seen below in a 
chart designed by P. Näätänen (Näätänen, 2010).  
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Figure 1 The structure of HUS psychiatry by Petri Näätänen 
The organization of secondary medical care in Finland is divided into twenty hospital 
districts. The Hospital district of Helsinki and Uusimaa (Helsingin ja Uudenmaan 
Sairaanhoitopiiri - HUS) is the largest of these [website]. It includes a total of 24 hospitals 
and represents 49 major medical specialties including surgery, anesthesiology, psychiatry, 
obstetrics and gynecology, neurology and oncology. HUS is then further divided into 5 
hospital districts: Hyvinkää, Lohja, Länsi-Uusimaa, Porvoo and HUCH (Helsinki University 
Central Hospital). Below are some key statistics of HUS: 
Hospital stays       498,592 
Bed days (psychiatry, respiratory paralysis patients)  294,627 
Outpatient visits      1,454,382 
Surgical procedures      85,823 
Deliveries       17,822 
Total of different persons who used the services  445,271 
Staff of HUS (31 Dec 2007)      21,202 
Operating income       1,404,4 Million EUR 
Operating expenses      1,320,5 Million EUR 
Population of Area (31 Dec 2007)    1,476,751 
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Helsinki University Central Hospital – HUCH (HYKS) 
HUCH is by far the largest hospital area within HUS, tending to over a million people in 
southern Finland. The 17 hospitals (including the major ones of Jorvi and Peijas) of HUCH 
are functionally divided into four main areas, called the profit units or the clinic groups: 
medicinal, operative, gynecology and pediatric care, and psychiatry. The medicinal unit treats 
allergy, skin and STD‟s, lung disease, neurology, cancer and internal disease. The operative 
unit includes surgery, anesthesiology, emergency treatment, pain treatment, ear and eye 
treatment, and neurosurgery. Gynecology and pediatric care consist of pediatrics, pediatric 
surgery, neurology, psychiatry, gynecology and child birth. Finally, the field of interest for 
this thesis is that of psychiatry. Its major fields are mood disorders, bipolar disorders, 
depression and schizophrenia. Some key figures about HUCH, which is by far the largest unit 
within HUS, in 2007: 
Treatment periods and day surgery treatments  401,400 
Outpatient visits      1,091,400 
Childbirths        14,100 
Number of individuals using the services   329,100 
 
The sample: depression in Jorvi and Peijas  
The sample selected for this study is depression and its treatment in the Jorvi and Peijas 
hospitals, that are the major sites for Espoo and Vantaa respectively. They both have a wide 
range of different specialty treatment but this study focuses on the psychiatric care in them. 
The reasons for choosing these particular hospitals were the following: the data was readily 
available and the hospitals are of similar status and size, making a analysis of any correlation 
in the results possible and interesting. The reason for choosing the treatment of depression is 
that, unlike other fields in psychiatry, the disorders and hence diagnosis and treatment for 
depression are considered to be a somewhat standardized and straight forward (unlike e.g. 
schizophrenia, where patients might stay in the system for years if not decades, presenting 
with numerous levels of severity, symptoms and undergoing various treatments). In addition, 
the number of patients in depression is very large, making statistical analysis of the data 
viable.  
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The challenges of the organization 
The psychiatry in HUS has seen several challenges surface (or resurface) with the recent 
economic downturn. There is a number of essentially strategic and political challenges as well 
as some practical and motivational ones. The strategic and political challenges are those that 
need to be considered or solved in the long run, whereas the practical ones are means to that 
end. This section identifies these challenges and then summarizes some immediate goals that 
are to be strived for in order for a major reform to prevail.  
 
Strategic and political challenges 
This section goes through some major issues that HUS has to face. Some of them are 
problems that should be addressed, and some of them are just facts that must be accepted as 
given. First paragraphs mention some strategic problems. The latter ones then put across some 
political realities that are unlikely to change in Finland any time soon.  
One of HUS psychiatry‟s central strategic challenges is low efficiency. There is a number of 
ways in which the efficiency of psychiatric treatment can be assessed (discussed in more 
detail further in the paper) but the general trend of public psychiatric care has been positive in 
the past decades. The “Mertu” –study conducted by the National Institute for Health and 
Welfare (Terveyden ja Hyvinvoinnin Laitos – THL) suggests that the trends aimed at higher 
efficiency have lead to remarkable improvement in overall mental welfare of Finland. 
However, challenges for these apparently beneficial reforms keep surfacing and resurfacing as 
they are further implemented across the country. 
A major strategic challenge is closely tied to the problem of low efficiency. There have been 
few efforts to battle the inefficiency as the organization appears to be stale and archaic; an 
organization in which old habits live strong, authority is spread to every professional (and 
medical doctors tend to be – or at least consider themselves to be – very professional), and 
change is hard to justify and implement. This situation has been improving recently and 
psychiatry has become less institutionalized (i.e. less patients are put into inpatient care and 
given humane conditions to survive), less psychotherapy oriented and more process driven. 
Even so, the culture is far from that of a private company and hence managers attempting 
reforms are often faced with the age old argument: “It has always been done like so. What do 
you know? Who are you to challenge the late greats?” To counter this problem, the current 
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management is attempting a strategy of re-engineering that is based on solid statistical proof 
whose validity and viability could not be challenged by the above argument. 
A major political challenge is the fact that HUS is a public health organization, and hence has 
a responsibility to the population and the management reports to the representing politicians. 
The actions of anyone attempting to implement changes are thus further bound by public 
opinion and worries about public image. It might often lead to a less than ideal decision being 
made for political reasons, rather than those of higher efficiency, better results or even 
common sense.  
Another central issue stemming from the public nature of HUS is that their funds and hence 
bargaining power is limited. According to (Palkkatietoa, 2009), a medical doctor in the 
private sector earns an average of €6,400 in 2008, whereas the equivalent figure for the public 
sector was over a €1,000 less. The initiative of a greater salary hence does not generally apply 
for the public sector, whereas the stability of a job and an opportunity to gain the experience 
of treating a wide range of patients (the patients in the private sector are of lesser variety; 
generally the kind that can afford to pay for private psychiatric treatment) are certainly factors 
that public sector doctors appreciate. Despite this, the incentive of a high paying job proves to 
be stronger as can be seen by ever worsening situation of public medical staffing (MTV3, 
2009). Having a smaller salary to offer its staff and being understaffed, public health 
organizations rarely have the luxury of haggling on working conditions with their employees 
and their managers‟ decision making power is hence further compromised.  
 
Practical challenges 
There are numerous practical challenges HUS is faced with. This subsection first mentions 
several typical ones and then moves to the ones that will be specifically addressed using the 
results of this study. 
The work group composition of a standard psychiatric outpatient station (Joffe, 2010) was 
first set back in the 60‟s. Each included one doctor, one nurse and one psychologist. The 
reasoning behind this composition was something like this: “In psychiatric treatment there are 
jobs for doctors, nurses and psychologists, so let‟s stick some (one) of each in the mix.” This 
issue is of major importance in terms of the efficiency of the whole system of psychiatric 
treatment, however it out of the scope of the current study. Attitude seen is this example has 
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been changing lately (and steps are being taken to adjust the balance of work force) but the 
fact that attitude towards strictly operational and economic issues has largely been 
unscientific and approximate. 
Another example of this point can be made of a related subject – the division of labor in 
treatment processes. A doctor‟s hourly pay is significantly higher than that of a nurse or a 
social worker – this is critical to cost efficiency, yet historically often overlooked. 
Standardized simple procedures like checkup visits (where a standardized questionnaire is 
filled out to see the effectiveness of the treatment, and any side effects are recorded) do not 
require the expertise of a doctor – they can be easily conducted by a nurse. Also, initial 
assessments of the severity and the diagnostic is usually done with standardized 
questionnaires that can also be conducted by a nurse (in some cases like the SCID –scale, the 
nurse would need some extra training). There are many other examples of doctors being 
overqualified for the actual tasks they are doing. However, due to a lack of standard procedure 
guidelines and clearly defined work assignments, this significant aspect of efficiency goes 
largely unaddressed.  
Another case where old, scientifically unjustified practices hold back the efficiency of the 
system is the length and the frequency of visits. According to the current perspective of (Aer, 
Oikkonen, & Riihimäki, 2005), outpatient psychiatric treatment has advanced significantly 
and have replaced many inpatient treatment methods. In addition, primary care has developed 
to be able to provide the treatment that was previously only available in secondary care. These 
include rehabilitation programs and chronic check-up visits for psychiatric patients. 
Outpatient care is also significantly more economical and is hence preferable in the current 
economic situation. Old habits tend to stick however and progress to reduce the proportion of 
inpatient care has been slow. When it comes to outpatient care, the Current Care Guidelines 
do specify, that during the treatment period, while a patient is undergoing therapy and / or 
anti-depressant treatment, it is necessary to let the treatment take some effect before meeting 
the patient again. In other words, meeting the patient every day during the treatment period 
would be generally useless (with certain exceptions, see “definitions” –subchapter) since the 
actual treatment has not had a chance to have an effect and alter the patient‟s condition. Thus 
the advised frequency of visits is once a week. But during the preliminary assessment period 
there is no medical reason to keep the visits so far apart, since there is nothing that needs to be 
allowed to take effect. There are practical reasons often referred to however, such as “We 
couldn‟t possibly force a person to miss up to three days of work.” In fact, the patient would 
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end up spending the same amount of time at the hospital, with more time spent on the 
additional trips. Also, one might think that treatment of a serious mental condition could take 
priority in a person‟s life for a number of days. According to (Aer, Oikkonen, & Riihimäki, 
2005), instead of spending several weeks conducting a single test per week, the assessment 
could be done in two or three days by simply having the patient come in on consecutive days 
for  a few hours each. Not only would this allow a decrease of the total time a patient spends 
in the system (and hence any possible costs associated) , but also to diagnose the condition 
and begin treatment sooner. What might at first seem like a lack of regard to the matter is 
actually probably best explained by the fact that there is no instructions or guidelines that 
would specify the medically (and economically) optimal way.  
Lack of regulated standards and practices is another major issue that affects the quality, the 
cost and hence the efficiency of treatment. There are no proper rules for the procedures that 
should be conducted and what order they should be conducted in (the existing guidelines are 
looked at in more detail below). The treatment procedures are actually determined by the 
doctor‟s experience and best judgment. One doctor might have found that a particular pair of 
drugs works well, and that certain kind of therapy is effective in a given situation. Another 
doctor might have had a different experience, would choose a different drug, a different 
therapy and hence a different treatment period pattern. One would hence expect a massive 
variance in treatment periods, and a large variance in a process is trouble. Things like the 
amount of mental health produced, the costs incurred, the work force required and the queue 
lengths are thus very difficult to estimate.  
In addition, not only are the expected values above difficult to estimate, they are not 
consistently measured either. At the moment there is a work group at HUS psychiatry that has 
set out to map the processes in the treatment of psychiatry (discussed in more detail below) 
but it is a first of its kind and is yet to measure the actual values of the aforementioned 
parameters. If key values of a given treatment path were measured, an optimal method of 
treatment could be found. This method would then be set as a standard that employees should 
follow. A standard could be something like this: “Treatment with drug X for six weeks works 
in 60% of the cases, this should therefore be the first option of treatment. If this did not work, 
the next best thing is drug Y along with therapy – this is effective for the next 60% (etc.). The 
effect of the treatment is to be measured with GAS (a scale of severity, explained below) and 
results compared against benchmarks and adjusted accordingly.” 
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 The fact of poor measurement of key parameters results in several effects: the optimal 
treatment methods are not found and specified (although there are consensuses, discussed 
below), queues grow, resources are used inefficiently, and targets cannot be set. And where 
goals are not set, employees cannot strive for them.  
 
Motivational challenges 
Motivation is an issue for any public organization. The employees are not rewarded per unit 
of work done and hence they have no financial motive to exceed themselves. In the case of 
HUS, employees do not work for pride for a unit either, since there is no culture of team spirit 
in the units. One might then argue that the employees work just well enough to appear 
satisfactory in the eyes of peers and superiors and hence keep their jobs, and to fulfill the 
moral obligation of working for their money – this leaves a lot of room for improvement. 
The absence of standards and target figures, along with the limited opportunity of financial 
incentives (thanks to the public nature of HUS) leads to the availability of few if any 
motivational tools. Motivating employees can be done (roughly speking)put by giving a carrot 
for reaching a set goal. The goal can be defined in a number of ways and the carrots could be 
various.  
Currently, to estimate the state of a unit, the management is forced to rely on such measures 
as the employees‟ willingness or unwillingness to work there. Obviously this cannot be 
measured, recorded or compared – and hence rewarding performance or dealing with 
problematic units becomes a matter of gut feeling or word of mouth. A well functioning unit 
has content and motivated employees and a high efficiency – it is hard to say which is the 
cause and which is the effect, but the two are correlated. Efficiency is a significantly more 
rational metric to use than the satisfaction of the employees, when judging the state of a unit. 
A possible metric that could be used to judge the state of a unit is the amount of quality 
treatment produced. It is difficult to define this metric, but one could perhaps use a morbidity 
scale such as the GAS. The following is a simple example of a quantifiable metric that could 
be set as a standard for an operational unit. A certain quality standard is set (e.g. a patient is 
healthy enough with a GAS score of X), and once it is achieved, the patient is discharged. At 
this stage it this is problematic however, since GAS is rarely filled in – there is no proper 
motivation to do so. The number of discharged patients in a given period would then show the 
16 
 
performance of that employee or unit. Other metrics that could be used for setting a standard 
to strive for are the rate of early retirements, the rate of suicides, a quality of life metric, the 
working ability of the patients and so on. This however is a topic best left for future research 
in this matter. 
The well performing units are then rewarded with either nominal recognition or with financial 
benefits and the poorly performing units are paid attention to and taken care of. The nominal 
recognition could be a plaque or a diploma given out to the best performing unit every month. 
This would get people to take pride in the performance in their units, morale and hence 
efficiency would rise. That might spawn some negative opinions, but does not seem 
impossible. The financial benefits are more difficult. Being a public institution an 
performance adjusted salary would provoke an uproar of dissatisfaction since people are used 
to the fact that a public sector job is a stable uniform position where the state always has your 
back. The political aspect spoils motivation also by the way in which the budget is determined 
– by the costs of previous years. This means that where savings are achieved with better 
efficiency, they are undercut but the state‟s policy of budget determination. This might be 
corrected by putting the issue across to the politicians, arguing that it is vital for efficiency. 
Perhaps a compromise could then be reached where half of achieved savings will be 
distributed as bonuses and half will be reduced from the next year‟s budget. 
Another problem that arises from the set salary that the employees get is that services that 
HUS should bill the clients (municipalities or adjacent medical organizations) sometimes go 
unrecorded. The most common example of this is a consultation: another hospital asks a HUS 
doctor for an opinion, either by phone or in writing. This service is not defines in the HUS 
psychiatry price list and is hence not recorded. The doctor‟s time is certainly spent on this 
activity, but the organization is not compensated for it, because there is neither opportunity 
nor motivation for the doctor to record this service. The management of HUS considers this to 
be a significant shortfall of the system resulting in a significant loss of efficiency – structures 
for its billing should be set up and employees should be motivated to use them. 
The questions of motivation are then quite vital for the organization as a whole. However, 
they will be addressed by the managers of the organization at a later time, once the grounding 
work – including this thesis – has been done.  
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Theory and background 
This chapter covers the theoretical aspects and definitions of concepts relevant to the thesis, 
as well as some examples of the techniques and tools in question have been implemented. 
These include information about the condition as well as its measures, definitions of some 
general treatment methods and finally the methods in which pricing of services is done in 
HUS. Each subchapter attempts to show some examples of how these concepts are presented 
in practice. 
 
Quantitative approach to mental health 
Mental health is historically looked upon as the more patient-doctor oriented field of 
medicine, whereas somatics are those that have been subject to the more process-oriented 
perspective. This is natural for a discipline that has relied heavily on psychotherapy, and 
appears to be vague and unstructured. Despite this public appearance of “softness”, 
quantitative approaches have been employed in psychiatry for years. Studies of drug 
efficiency for example are reported in quantitative terms, much like procedures in somatics.  
What comes to processes in mental health, a major authority in this field is Dr. Richard C. 
Hermann from the Tufts Medical Center in the US. He heads an institute devoted to defining, 
measuring and improving quality in mental health. In addition to numerous articles on the 
quality in mental health, Dr. Hermann was the chairman of a committee for Organization for 
Economic Co-operation and Development of the OECD involved in producing a report 
entitled “Selecting Indicators for the Quality of Mental Health Care at the Health Systems 
Level in OECD Countries”, and wrote a book “Improving Mental Healthcare: A Guide to 
Measurement-Based Quality Improvement” (Hermann, 2005). The former is largely 
influenced by the latter. 
The book is divided into two parts where the first one covers the approach, while the second 
summarizes the developed measures over the course of some 500 pages. While unfortunately 
mostly inapplicable in the current study (due to limited data, benchmarks and targets of this 
study), the work of Dr. Hermann is an excellent example of the quantitative approach to 
mental health processes and structures.  
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The variables are first classified into “Structural”, “Process” and “Outcome” measures. These  
include “Clinician characteristics”, “Facility characteristics”, “Financing characteristics”; 
“Interpersonal processes”, “Technical processes”; “Symptoms”, “Functioning”, “Quality of 
life” etc. respectively. The actual measures such as “Visit frequency for depression treatment” 
could be incredibly useful if relevant benchmarks and records were kept. Alas, these are not 
currently done consistently in Finnish mental health care and thus cannot be properly 
analyzed. For future efforts to improve the quality of mental health care these could be of 
paramount importance. This study thus does recognize the existence on this vast and in depth 
work on the quality of mental health care but chooses to use the standards defined specifically 
for the Finnish mental health care system as they are more applicable.  
 
The disorder and its measures 
Depression is a major cause of disability pensions in the modern world. Hence, it is a 
significant burden for a society. This section describes the disorder in question, how 
significant it is in social terms and what tools are used to measure it.  
 
Depression 
According to (WHO, Depression, 2010), depression is a common mood disorder that has 
symptoms of depressed mood, loss of interest or pleasure, feelings of guilt or low self-worth, 
disturbed sleep or appetite, low energy, and poor concentration. These symptoms might 
present in different severities or combinations whose levels are evaluated with assessment 
scales such as the ICD-10 (described in more detail below), and hence the treatment for each 
might differ.  As with many other mental disorders, depression can be treated by altering the 
brain chemistry with psychoactive drugs, or with therapy that induces a change of brain 
chemistry with substances naturally occurring in the brain. In addition, for very severe cases, 
electroconvulsive therapy (ECT) might be employed as a last resort of treatment. It‟s effect 
can be characterized by a comparison with a reset button on a computer. The optimal choice 
of treatment methods is described in the Current Care guidelines below. 
Depression is also amongst the leading causes of disability worldwide affecting some 121 
million worldwide (WHO, Depression, 2010). In 2000, depression was ranked as the 4th 
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leading contributor to the global burden of disease as measured in DALY‟s.  Since depression 
reduces both the quality life span as well as the total life span of a patient, it is a major 
financial issue for the national economy. According to the Finnish Center for Pensions (ETK, 
2009) depression as a cause of early pensions has grown ten folds since the beginning of the 
80‟s. The report does however underline that the number of cases of depression has not grown 
significantly since then. This development of early retirements due to depression makes 
research into the efficiency of its treatment even more current.  
 
Social measures 
An important social metric on the significance of a condition on a population is the Disability 
Adjusted Life Year (DALY). It is used to estimate the disease burden of a given condition on 
a population. DALY was first used by WHO in a global burden of disease study in 1996. 
Since then it has become a standard metric of the effect of a condition on a population. DALY 
is determined by the combination of two factors: Years of Life Lost (i.e. premature death) + 
Years Lived With Disability. The higher the value, the more the disease shortens the lives of a 
population. Critically however, the DALY is a lso weighted by a person‟s age. This is to 
account for the fact that young adults are considered to be the most valuable for a society – 
they have a lot invested in them, they have a lot to give back. The weighing according to age 
used by the WHO looks as follows: 
 
Figure 2 Age weighing in WHO's DALY analyses 
The proportion of depression in terms of age-adjusted DALY vs. the total DALY in Finland is 
some 12%. This is a significantly higher than the global average of approximately 5.2%. This 
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can be explained by the fact that conditions like HIV are not plaguing first world countries 
such as Finland. The fact remains though, that according to WHO measures, depression is 
proportionally as big an issue for Finland, as HIV is for Sudan. 
Other important social metrics include demographic data such as early pensions, suicide rates 
and work ability. The Finnish Center for Pensions and Statistics Finland keeps records of 
early pensions and reasons for them. According to (Gould & Nyman, 2004), the number of 
early retirements due to depression has quadrupled since the 80‟s (although the condition has 
not become more common) and in 2003 accounted for as much as 16% of total early pensions 
in the private sector. In 2007, depression resulted in 32000 absences and some 4600 new early 
retirements in Finland (Käypähoito, 2009). Depression is also the most common contributing 
factor to suicides in Finland, where 66% of all suicides involved some level of depression 
(Lönnqvist) (worldwide, the equivalent value is only 30% (Bertolote, Fleischmann, De Leo, 
& Wasserman, 2004)).  Globally, according to 2007 data by (WHO, Country reports and 
charts available, 2009), Finland was ranked 15th in suicides, with 18.2 suicides per 100,000 
inhabitants. Hence, according to the major social metrics of early retirements and suicides, 
depression can be said to be a major social issue for Finland. 
Another metric that can be considered both social and clinical, is the Social and Occupational 
Functioning Assessment Scale (SOFAS). It evaluates the condition of the patients in terms of 
their adaptability to the society, their ability to work and their interpersonal skills 
(Psychiatryonline, 2008). This scale differs from previous scales such as the Global 
Assessment of Functioning (GAF) in that it does not depend on the clinical severity of the 
condition – it only focuses on the patient‟s level of social functioning. Amongst other things, 
this means that the scale can (and is) used for a number of conditions including schizophrenia 
and depression. The results of the scale rate the patient somewhere in the range of 10-100, 
where 100 is “Superior functioning in a wide range of activities”, 50 is “Serious impairment 
in social, occupational, or school functioning (e.g. nor friends, unable to keep a job)” and 10 
is “Persistent inability to maintain minimal personal hygiene. Unable to function without 
harming self or others or without considerable external support.” The use of SOFAS in HUS 
has been increased and promoted in the past years. However, the records are not yet 
consistent enough for the current study to use them. 
The above social metrics are just examples of numerous possible ways to measure the health 
of a society or an individual (in terms of social skills). These measures are important when 
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investigating the effect of a type of treatment on a society, when building a major picture of 
chains of causes and effects between treatment procedures and the health of a population. 
Despite being interesting and vital from the wide perspective, these metrics are not in a major 
role in this study, for the following reasons. First, the scale of the study would change to 
another order of magnitude – it would be a task suited for several doctoral theses rather than a 
single master‟s thesis. Second, the permissions for the data from KELA would have been 
likely to take several months to get; this was not compatible with the schedule. Third, this 
paper uses the Current Care Guidelines as medically sound facts, and checking their validity 
(by an analysis of social metrics) is a major medical research project (that has already been 
done) way outside of the scope of this study.  
 
Clinical / outcome measures 
The immediate effect (vs. the societal effect) of treatment is assessed by clinical metrics – 
those that measure the severity of a condition. In addition, other clinical assessment scales are 
used to conduct the initial diagnosis of a condition. When patients come in for the first visit, 
their condition is measured with a clinical metric and diagnosed accordingly and they are then 
(ideally) treated according to the accepted standard. A clinical assessment scale can be 
performed in a number of ways, depending on the time and skill available as well as the 
desired precision of the results. These include questionnaires filled in by the patient, 
standardized sheets filled in by nurses or clinicians, or open-ended questionnaires where the 
latter questions depend on the former ones. The work, time and hence costs associated with 
each vary greatly. 
A pair of commonly used scales to diagnose depression is the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV, published by the American Psychiatric Association) 
and the International Statistical Classification of Diseases and Related Health Problems (ICD-
10, published by the WHO). (Mezzich, 2002) has shown that DSM-IV is preferred for 
research purposes whereas the ICD-10 is preferred by clinicians. As summarized by 
(Gruenberg, Goldstein, & Pincus, 2005) , the definition of depression by the ICD-10 (as it is 
defined by the current care guidelines) and by DSM-IV is the following: 
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DSM IV ICD-10 depressive disorder 
Clinical significance 
Symptoms cause clinically 
significant stress or 
impairment in social, 
occupational or other 
important areas of 
functioning. 
Some difficulty in continuing with ordinary work and social activities, but 
will probably not cease to function completely in mild depressive episode; 
considerable difficulty in continuing with social, work or domestic 
activities in moderate depressive episode; considerable distress or 
agitation, and unlikely to continue with social, work, or domestic 
activities, except to a very limited extent in severe depressive episode.  
Duration of symptoms 
Most of day, nearly every 
day for at least 2 weeks. 
A duration of at least 2 weeks is usually required for diagnosis for 
depressive episodes of all three grades of severity.  
Severity 
Five or more of following 
symptoms; at least one 
symptom is either depressed 
mood or loss of interest or 
pleasure:  
(1) Depressed mood  
(2) Loss of interest  
(3) significant weight loss or 
gain or decrease or increase 
in appetite  
(4) Insomnia or 
hypersomnia  
(5) Psychomotor agitation 
or retardation  
(6) Fatigue or loss of energy  
(7) Feelings of 
worthlessness or excessive 
or inappropriate guilt  
(8) Diminished ability to 
think or concentrate, or 
indecisiveness  
(9) Recurrent thoughts of 
death, recurrent suicidal 
ideation without a specific 
plan, or suicide attempt or a  
specific plan 
Depressed mood, loss of interest and enjoyment, and reduced energy 
leading to increased fatigability and diminished activity in typical 
depressive episodes; other common symptoms are:  
(1) Reduced concentration and attention  
(2) Reduced self-esteem and self-confidence  
(3) ideas of guilt and unworthiness (even in mild type of episode)  
(4) Bleak and pessimistic views of the future  
(5) Ideas or acts of self-harm or suicide  
(6) Disturbed sleep  
(7) Diminished appetite  
Typical examples of “somatic” symptoms are: loss of interest or 
pleasure in activities that are normally enjoyable; lack of emotional 
reactivity to normally pleasurable surroundings and events; waking in 
the morning 2 h or more before the usual time; depression worse in the 
morning; objective evidence of definite psychomotor retardation or 
agitation; marked loss of appetite; weight loss; marked loss of libido. 
For mild depressive episode, two of most typical symptoms of 
depression and two of the other symptoms are required. If four or more 
of the somatic symptoms are present, the episode is diagnosed: With 
somatic symptoms. For moderate depressive episode, two of three of 
most typical symptoms of depression and at least three of the other 
symptoms are required. If four or more of the somatic symptoms are 
present, the episode is diagnosed: With somatic symptoms. For severe 
depressive episode, all three of the typical symptoms noted for mild and 
moderate depressive episodes are present and at least four other 
symptoms of severe intensity are required.  
 
As mentioned above, depression diagnosis is classified according to the number of symptoms 
present in a patient. The current study was initially planned to consider the two major groups 
of depression – F32 and F33. However, as the aim of this study is to give an example of a 
baseline analysis of a treatment method most likely to be easily standardized (as F32 is 
expected to be), the sample was quickly cut to only include patients with a diagnosis of F32. 
In addition, patients who were first treated for F32 and later for F33 would make the analysis 
excessively complex. 
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Their subgroup and definitions by ICD-10 are the following: 
F32 Depressive Episode 
F32.0 Mild depressive episode 
F32.1 Moderate depressive episode 
F32.2 Severe depressive episode without psychotic symptoms 
F32.3 Severe depressive episode with psychotic symptoms 
F32.8 Other depressive episodes 
F32.9 Depressive episode, unspecified 
F33 Recurrent depressive disorder 
F33.0 Recurrent depressive disorder, current episode mild  
F33.1 Recurrent depressive disorder, current episode moderate  
F33.2 Recurrent depressive disorder, current episode severe without psychotic symptoms 
F33.3 Recurrent depressive disorder, current episode severe with psychotic symptoms  
F33.4 Recurrent depressive disorder, currently in remission 
F33.8 Other recurrent depressive disorders 
F33.9 Recurrent depressive disorder, unspecified 
 
The above classification will be discussed in more detail further on, in the data analysis 
section. The reason for its introduction here is to show that depression (as many other 
disorders) is classified somewhat strictly according to a preset framework of criteria. The 
treatment procedure is hence selected to fit the subcategory of the condition, and precisely 
those procedures are described in the Current Care Guidelines.  
Once the patient has been diagnosed with depression they are admitted into care and the 
severity of their condition (i.e. morbidity) is monitored. Ideally, this is done at initial 
admission, at the end of treatment and at intervals during treatment. A tool that can be used 
for this type of monitoring is the Global Assessment of Functioning (GAF). This 
questionnaire assesses the social functioning of a patient in terms of the symptoms of the 
disorder. It takes some 20 minutes to conduct and rates the state of the patient on a scale of 
10-100. It has been recently taken into extensive use in HUS to gauge the effectiveness of a 
treatment. (Wahlbeck & Tuori, 2009) report that over 95% of inpatient stays have had their 
GAS-scores recorded at the beginning and at the end of the stay. However, by a preliminary 
estimate it is not recorded consistently enough for treatment periods in the outpatient care to 
be analyzed in this study. Where applicable however, as it has been done in (Wahlbeck & 
Tuori, 2009), it can be used to estimate benchmarks for how much treatment is sufficient 
(country wide average was 39,0 points at entry and 51,2 points at departure from inpatient 
care treatment). Theoretically, for outpatient care, it could also be used to suggest an optimal 
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treatment method. For example, “a patient with a GAF score of less than 70 should be given 
type 1 treatment. If this didn‟t increase the GAF score, treatment 1.1 should be performed.” 
 
Monetary measures 
The QALY on the other hand is a tool used to evaluate the efficiency of a medical 
intervention. It considers the cost of the medical procedure and the QALY‟s gained by that in 
terms of a cost per QALY and the resulting value can be used to see whether a given 
treatment is cost efficient (according to (NHS, 2010), if the cost per QALY exceeds £20,000 - 
a£30,000, the treatment is considered not cost efficient). The QALY is calculated by 
assigning a weight to a patient‟s life year depending on the severity of the condition. A 
perfectly healthy person would have a coefficient of 1.0, and a dead person would have a 
value of 0.0. Below is an example of a QALY calculation from (NHS, 2010): 
Patient x has a serious, life-threatening condition. 
 If he continues receiving standard treatment he will live for 1 year and his quality of life will be 0.4 
(0 or below = worst possible health, 1= best possible health) 
 If he receives the new drug he will live for 1 year 3 months (1.25 years), with a quality of life of 
0.6. 
The new treatment is compared with standard care in terms of the QALYs gained: 
 Standard treatment: 1 (year’s extra life) x 0.4 = 0.4 QALY  
 New treatment: 1.25 (1 year, 3 months extra life) x 0.6 = 0.75 QALY 
Therefore, the new treatment leads to 0.35 additional QALYs (that is: 0.75 –0.4 QALY = 0.35 
QALYs). 
 The cost of the new drug is assumed to be £10,000, standard treatment costs £3000. 
The difference in treatment costs (£7000) is divided by the QALYs gained (0.35) to calculate the 
cost per QALY. So the new treatment would cost £20,000 per QALY. 
 
In addition to the above method of assessing the viability of treatment for a single patient, the 
financial department can measure other factors in terms of costs. For example, if general data 
such as early pensions caused by depression in a given population were easily available, they 
could be measured against the overall costs of treatment methods and organizational structure. 
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This is however a major process that would require a thorough analysis of demographics, the 
causality would be very difficult to determine and the whole study would likely take years. 
For the purpose of this study however, the Current Care Guidelines are taken as the medical 
truth. They do specify what level of morbidity (severity of condition in terms of symptoms) 
requires the costly specialized care of secondary health care (erikoissairaanhoito), and which 
patients should rather be treated in primary health care (perusterveydenhuolto). As said above, 
this is the central question of this study – how does reality differ from the guidelines and 
hence how much costs does HUS (and consequently the society) bear as a result of excessive 
treatment in secondary health care.  
 
Treatment methods 
This section covers some central concepts and standards associated with treatment methods of 
depression. First, a distinction between outpatient and inpatient care is explained. Second, the 
official standard of treatment of depression is described. Third, a more general treatment 
framework based on both the CCG and experience of doctors is presented.  
 
Outpatient vs. inpatient care 
The two basic types of clinics that this study is concerned with are outpatient and inpatient 
care clinics. The principal difference is in that at an outpatient care clinic does not keep 
patients overnight; rather they only come in for visits. This type of care is also sometimes 
referred to ambulatory care. Inpatient care on the other hand is the kinds where patients are 
signed into a hospital for a stay. There a certain significant advantages in outpatient care and 
the government has been promoting that method over the traditional hospitalizations.  
According to (Wahlbeck & Tuori, 2009), out of the Nordic countries, Finland currently has by 
far the greatest proportion of hospital spots, almost 1,0 per 1000 inhabitants. This is despite 
the fact that the amount of inpatient patients in psychiatry has decreased to a quarter of what it 
was in the 70‟s (although the aim is about 0,5 spots per 1000 people, like Sweden currently 
has). The progress thus far is a result of the modern treatment policy that promotes outpatient 
care because rather than giving mental patients a humane place to exist (i.e. commit them to 
an institution), they are quickly treated and re-established in the society. In addition, out care 
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patients are not cut from their social networks for the duration of the treatment. Finally, 
outpatient care is significantly cheaper than inpatient care – reducing the proportion of 
patients receiving inpatient treatment, along with shortening treatment periods, is one of the 
principle methods of reducing costs in psychiatric healthcare. Finland has made considerable 
progress, but there is still plenty of room for improvement.  
 
Current Care Guidelines – CCG (käypä hoito suositukset) 
The Current Care Guidelines for depression were developed by a work group headed by Erkki 
Isometsä in 2004 (Käypähoito, 2009). They are based on an extensive analysis of 
international (controlled) studies of the condition. Once the diagnosis has been made 
according to the ICD-10 criteria described above, the CCG define an optimal treatment 
method for depression in terms of the medicine used and procedures performed (this entirety 
of treatment procedures and visits is called “hoitojakso” and referred to as “treatment 
package” in this paper) . Although they are in a central role for the analysis of the results of 
the current study, one must keep in mind that they apply to both primary health care (not 
investigated here) as well as secondary health care. The expected results of this study are thus 
expected to differ significantly from the values presented in the CCG. However, the main 
argument for change will remain: if the treatment described in the CCG has not had an effect, 
it is no longer rational to keep the patients in the secondary health care system, and they 
should be transferred to primary health care where they will are provided with ways to cope 
with their condition (e.g. support groups). A short version of some key components of the 
CCG are presented below: 
 Depression is treated in 3 major stages as shown (acute, continuation, follow up):
 
Figure 3 Stages of treatment of depression according to the CCG  
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 The aims of each stage are: 
- acute treatment: remission of symptoms, should be conducted until this goal is 
achieved (e.g. under 8 points on the Hamilton scale, or under 10 points on the 
Beck scale) 
- continuation treatment: to prevent the resurfacing of symptoms (relapse) 
- follow-up treatment: to prevent an onset of a new depressive episode  
 The techniques that can be used in the acute phase: 
- psychotherapy 
- medication 
- the both above 
- in some cases ECT 
 Regardless of treatment method, a depression patient requires checkups during acute 
treatment and for at least half a year hence 
 The effectiveness of treatment and morbidity is to be monitored at the checkup visits  
 The time frames can be summarized as follows: 
- the symptoms of 40-50% of patients disappear in 6-8 weeks of drug treatment, 
and another 15%-25% of patients have a partial response (treatment should 
still be continued as remission would otherwise be very likely) 
- visits in the acute phase should be frequent (once in 1-3 weeks, even more 
often if self-destructive tendencies are significant) 
- if there is no significant response to treatment in 6-8 weeks of drug treatment, 
medication should be reconsidered 
- drug treatment should be ideally continued for 6 months after the remission of 
symptoms 
- in cases of third or more recurrent depressive episode, drug treatment should 
be continued indefinitely, and check-up visits should be conducted at least 
once every 6 months 
- psychotherapy in the acute phase is alone effective for about half of patients 
within 4-6 months 
- the acute phase and the continuation treatment should thus take up to 9 
months: up to 1 month of evaluation (can be less), up to 2 months of drug 
treatment, up to 6 months of combination of drugs and therapy 
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 A vast majority of depression patients can be effectively treated in primary health 
care: 
- mild depressive episodes with a good response can be effectively treated 
according to the above guidelines 
- the continuation phase and especially the follow-up phase can be conducted by 
depression nurses (depressiohoitaja) where procedures and methods are 
standardized and the cost of personnel is lower 
- psychiatric consultation must be available to the primary health care staff for 
cases where the qualification is insufficient yet there is no apparent need for 
specialized care 
- the main causes for directing a patient into secondary health care are: 
 severe or psychotic depression 
 drug resistant depression 
 a patient with multiple diagnoses or severe self-destructive tendencies 
- the estimate of a proportion of patients referred to secondary health care is 5-
12% 
 A number of quality criteria are also suggested in the CCG, however without 
definitive benchmark values. Some of them are: 
- is the number of patients with a depression comparable to the national average  
- what proportion of patients has received medication 
- in what proportion of cases have clinical measures been employed  
- what proportion of patients achieve complete remission 
In an interview, Dr. Isometsä (the chairman of the committee responsible for CCG of 
depression) agreed to the following pattern of depicting the acute phase treatment process in 
terms of time. Class 1 patients (nominally, in terms of severity and responsiveness to 
treatment) comprise some 40-50% of the total, and they respond to solely drug treatment with 
a remission of symptoms. Class 2 patients (more resistant to treatment) would carry on to 
therapy along with a drug treatment for a number of weeks. Class 3 patients would require 
electro-convulsive therapy (ECT). Although this division was crude, it shows the pattern and 
the approach in which patients can be divided up into severity classes and hence the durations 
of their treatment would be different. The current study will refer to the CCG when 
comparing the durations and frequencies of visits in the sample data. 
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General consensus of HUS management 
Based on the Current Care Guidelines and clinical experience, a group of doctors (includes 
the head of HUS psychiatry, main clinicians of Jorvi and Peijas) at HUS have defined an 
approximate treatment path for a depression patient. The idea is that this standardized 
treatment method could simplify billing and streamline processes. Unlike the CCG, it is 
unofficial and the times are not defined explicitly. In fact, this study might be used to adjust 
the exact time periods of treatment and the allowed variances. Several things are clear in this 
proposed model: a) there are clearly defined time periods b) there are clearly defined 
frequencies of visits c) there are several exit points for patients in the process. In terms of the 
number of patients in a system for the duration of the treatment, the pattern should roughly 
look as follows: 
 
Figure 4 Proposed generic model of treatment of depression 
Similar to the CCG, this proposed model would have a number of patient groups (labeled 
above as “Class X”), and they would leave the system at given points in time. In the above 
example, time 0, where class 1 (those that are found not applicable for this treatment) leaves 
the system, could be the first visit where an initial analysis is made. T=2, where class 2 
leaves, could be the point where medicinal treatment has taken effect and additional treatment 
is not needed. Exit point of class 3 would be the point where medicine + therapy has taken 
effect and class 4 would be where ECT was effective. Class 5 would then be the patients 
whose condition did not respond to the standard treatment (Dr. Isometsä mentioned in his 
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interview that this amounts to approximately 10% of the total, significantly higher for those 
who end up in secondary health care). The consensus suggests, that these 10% (class 5) 
should still be removed from the system into primary health care since the specialized 
treatment available in secondary health care does not benefit them. Primary health care would 
treat these individuals with a more gradual method, which requires less expertise but more 
time. This treatment (regular check up visits, occasional doctor visits and support group 
activities) is largely performed by depression nurses and social workers who have received 
additional training, but who are still less qualified and hence less costly than specialized 
doctors. 
 
Pricing 
The two principal approaches to pricing that are used in public health care in Finland are 
treatment process pricing and single procedure pricing. The two are principally different in 
their applicability, in their determination, in their motivational aspects and in their complexity 
in terms of billing. This section goes through the two basic ways in which psychiatric 
treatment in Finland (in fact medical treatment in general) can be priced. First, the single 
service approach is covered. Then, the package-based approach is explained in some detail 
and its most prominent example, the DRG, is introduced. Finally, some special cases of 
pricing are mentioned. 
 
Per-service  
The service-pricing approach sets a standard cost for a service and bills the patient 
accordingly. Generally, these include visits to a doctor, visits to a therapist, an ECT session, a 
day of treatment at the hospital and so on. This is the approach by which pricing has 
traditionally been done in psychiatry in Finland.  More specifically, since psychiatry does not 
have somatic treatment services (e.g. surgery) save for ECT, the two main billing articles are 
“an outpatient visit” and “a day of inpatient care”. These services have set costs that are listed 
in the HUS price list. How the pricing works on practice, will be shown in the data analysis 
chapter (and the official price list for 2010 can be found in appendices). As a result, the bill 
for a patient is ought to be larger if the number of visits is greater, and significantly larger if 
the patient spends time in inpatient care. On the other hand, if a patient only visits the 
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outpatient clinic once, they will be charged for that single visit. However, if a patient is 
treated “excessively”, the bill will keep on growing as the visits accumulate (and it will be 
respectively smaller if a patient does not finish a treatment plan, i.e. quits taking the medicine 
ahead of time). In other words, although this method is clear and simple in terms of billing, it 
lacks the remarkable trait of the latter alternative of pricing: motivation to stick to standard 
procedures. 
 
Per-package 
The treatment package pricing approach bills a patient for a whole standard procedure of 
treatment. The central benefit of this pricing system are its motivational aspects: excess 
treatment would be avoided by the personnel since it would still be billed by the average, and 
patients would be more motivated to stick to the treatment plan since the whole thing will 
have been paid for. This raises the question of whether the patients would be given sufficient 
treatment. But it is answered by the fact that extreme cases (really short or really long, over 
2SD off the average) are still billed by the simpler pricing method.  
In somatics (in fact, in all medical fields except for psychiatry), this approach has been 
implemented widely with a pricing tool called the Diagnosis-Related Group (DRG) since the 
early 90‟s (psychiatry was then left out of the reform). Dr. Jorma Lauharanta has been 
actively involved in that implementation of DRG and below is a short version of his 
explanation of the approach: 
- the total costs of a single patient are considered as follows 
 
Figure 5 An example of the composition of the total cost of a treatment package 
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- a sample of total costs is plotted on a histogram 
- data points outside ±2SD are dismissed as outliers, the ones within are 
considered “normal” processes 
 
Figure 6 The method of finding an average cost for a treatment package 
- if a package cost lies within the normal range, it is billed by the average, 
otherwise by single procedures 
The DRG scale is then further refined with weighting of procedures so that a per-DRG point 
scale can be constructed. This can then be used to investigate the efficiency of given 
procedures in terms of the big picture of  field of medicine. According to (Lauharanta, 2009), 
in addition to DRG improving the quality of data making efficiency tracking possible, it 
actually increases efficiency itself dramatically, as shown below: 
 
Figure 7 The increase in efficiency from 2007 to 2008 in terms of DRG / employee yrs 
Alas, this technique is not used in psychiatry due to some limitations that are discussed next. 
A study assessing the applicability of DRG was conducted at the university of Oulu, and 
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published as a graduate thesis entitled “Diagnosis based grouping logic for pricing psychiatric 
care ward episodes – NordDRG in adults psychiatry”. It suggests that DRG is poorly 
applicable to psychiatry for the following reasons: 
- There are too many DRG classes which results in some groups being too small 
to get a distribution where a reasonable average can be calculated  
- Some groups are too big (or vaguely defined) which results in huge variance of 
treatment costs within groups – again, no reasonable average possible 
- Treatment packages are not defined and hence recorded poorly 
- When constructing a DRG, the sample size is limited to a single hospital since 
the treatment practices vary greatly across hospitals 
- The study thus suggests that 
 the DRG classification should be revamped to reflect patient groups 
and treatment methods more accurately 
 use of DRG in pricing of long term conditions should be scrutinized  
So according to this empirical quantitative study, the shortcomings of DRG in psychiatry can 
be essentially attributed to the lack of standard procedure. If there were standards (as the 
current study is attempting to promote), there would be sufficiently large sample groups, there 
would be less variance in the treatment groups and so rational DRG‟s could be developed for 
psychiatry. In addition, the current study addresses the question of treatment standardization 
in depression, which the HUS management believes to be a process homogenous enough to 
be packaged into a DRG-like group (or several DRG-like groups). 
 
Additional services 
“Additional services” refers here to a number of additional services mentioned in the HUS 
price list including consultations, phone calls and letters. The number of these services is 
ought to be increasing with recent developments of increasing the proportion of patients in 
primary health care and using consults from secondary health care for support. At the current 
stage however the general attitude towards billing of these services seems inconsistent. With 
no precise guidelines and a lack of motivation to do so, they go largely unrecorded whereas 
they could ideally comprise a significant part of income for HUS. Due to the lack of their 
consistency, they cannot be properly analyzed in the current study.  
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Data gathering 
This chapter describes the process of data gathering and assesses the quality and the 
applicability of the data. The first subchapter deals with the process of getting the necessary 
data and mentions some difficulties encountered during. It includes an assessment of quality 
and applicability to the study and hence the reasoning behind data selection. The second 
subchapter goes through the process of data refinement, the reasoning for it and the end result 
– the data left for final analyses.  
 
Raw data 
This subchapter deals with the raw data: of how it was obtained, of its quality and its 
applicability. This stage of the study turned out to be a lot more cumbersome than initially 
expected because of mainly technical issues. Unexpectedly, a lot of time had to be devoted to 
the actual extraction, to reformatting and to the assessment of applicability. In addition to 
different formats, a lot of the raw data fields would be tautological (e.g. “duration of visit” 
and “number of days spent at visit” are essentially the same thing; they probably exist for 
technical reasons), and a lot of it could not be used for further analyses at all (e.g. “quetype”, 
the type of queue) and another lot was of unusable due to poor recording quality.  
 
Data gathering process 
The main source of data for the current study is the HUS IT system called Ecomed, developed 
for tracking patient records by Datawell Oy. Information about every patient visit at HUS is 
kept in this database. Its central benefit for this study is the fact that there is no personal data 
within it – all records are recorded with a nominal Patient ID, a value assigned to a patient 
with references to personal information stored in another database. The software itself is tied 
to a massive database of patient records, and it has a number of very useful tools for data 
analysis. In addition to a wide array of query possibilities, it can present the data in terms of 
histograms, distributions etc. However, to derive some central variables out of the data would 
have required exporting the data into a spreadsheet software such as MS Excel for a number 
of manipulations to be performed.  In addition to this, learning the use of Ecomed would have 
been necessary to be able to perform the desired analysis. Moreover, Ecomed is only available 
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on HUS intranet – a system that would have required permissions for the performer of the 
study or the use of guest credentials and a personal presence at the organization. Neither of 
these options was impossible, but logistically complex and more time consuming than the 
exporting of data. The problem with exporting however was that the needed data was only 
possible with some indexing values and a small number of queried variables, whereas the 
necessary complete information was impossible to retrieve with the Ecomed interface in HUS 
intranet. An access to the complete database was hence necessary – a privilege only available 
to the administrators of the database, Datawell personnel.  
For the above reasons a decision was made to contact Datawell and ask for a data extraction 
directly from the database into an Excel file (straight from the source, so to say).  Mr. Riku 
Kuikka was the contact person who promptly extracted the requested data from the database 
and placed it in compressed files onto HUS intranet. The files were then retrieved and 
combined into a single database of 178 columns by over 200,000 rows. There were some 
technical difficulties in this process as the older of version of Excel used only supported some 
65,000+ rows of data, the columns were in different orders and formats in each file (each file 
corresponded to a single year of observations). The combination (and hence sorting and 
formatting) process was painfully slow as the file grew to over 120 MB in size and the study 
computer was struggling to deliver the processing power required. An example of a 
frustrating outcome at this stage was the following: sorting by patient ID was started and the 
computer would descend into a state of processing. Some 30 minutes later it would return an 
error claiming “insufficient memory with given resources”. The data would then have to first 
be sorted in smaller batches and combined into the final file.  
 
Assessment of the Raw Data 
The problem of limited resources was overcome and a final version of raw data was obtained. 
Although very comprehensive and hence useful for the study, it was still grossly huge and 
thus unworkable. There was also an immense proportion of irrelevant or poorly recorded data 
(this would be later refined in later stages). An analysis of the raw data is still useful to 
illustrate the levels of data recording and possibly excessive holding capacity costs. The full 
list of data fields is available in the appendices. 
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General Description 
The data is comprised of every visit to HUS of patients with diagnoses F32 and F33 
(depressive episode and recurrent depressive disorder respectively) from treatment points of 
Jorvi and Peijas hospitals for 6 years, 2004-2009. This means a total of 223,520 rows of data 
across 177 columns. Both diagnosis groups F32 and F33 were included “just in case”, but F33 
was later discarded (by a suggestion of the client) since the treatment for a recurrent 
depressive episode is different from that of a first depressive episode, it has greater variability 
and is hence a lot more complicated to package into a standard treatment path. The reason for 
extracting data just from Peijas and Jorvi (as mentioned before) was to keep the possibility to 
analyse the impact of different treatment cultures in hospitals of comparable sizes and 
practices. The most crucial point about the selected data is time period, for 6 years from 2004 
to 2009. This was done to ensure that as much of the data as possible would consider the true 
irst and last visits (since it was unknown whether markers for first visit and last visit were 
consistently available in the data, later found to be inconsistent), rather than just the first 
recorded visit. Duration of treatment is defined as the time (in days) between the first and the 
last visit, illustrated below: 
 
Figure 8 Bias towards shorter periods due to the lack of markers of star and end 
The wider the range of observations, the smaller the proportion of untruly short treatment 
periods. This would create a bias towards shorter treatment periods, since it might be 
impossible to determine the true first and last visit and the “untrue” treatment durations would 
be indistinguishable from “true” durations (this question is addressed later in the data analysis 
chapter). In fact, when the durations of treatment were calculated for a single year, a large 
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number of patients appeared to be treated for the full year (whereas in fact, their treatment 
started before, and ended later).  
 
Data of Poor Quality 
A number of columns in the raw data at first appeared to be very valuable for the study but 
later turned out to be of too poor quality to used.  A central reason for this is the fact that 
treatment periods (or paths, or packages – “hoitojaksot”) are not used in psychiatry. What is 
officially referred to as a treatment period is a number of visits and procedures to compile a 
complete treatment path (versus “all visits between the first one and the last one”). Not 
surprisingly, as treatment periods (or packages – “hoitojaksot”) are not used in psychiatry, 
their markers such as “first visit” and “last visit” are not consistently recorded in the database. 
In fact, they would only be recorded if treatment packages were defined and followed. As a 
consequence, it would remove the need for a study as this one – since packages were known 
and defined anyway. Some data that was thus discarded included such variables as “complete 
treatment package”, “ended treatment package”,  “GAS at beginning”, “GAS at end” (as 
mentioned before, GAS is consistently tracked for inpatient stays, not outpatient packages),  
“DRG”, “date of beginning of queuing”, “queue days”, “psychiatric drug treatment”, 
“urgency level” and “product”. It is impossible to give a quantitative analysis of the level of 
inconsistency of data recording since it is essentially non-applicable to a system with no 
defined treatment packages. For example, it is impossible to say how many “start of queuing” 
records are missing since it is not explicitly defined, what this queuing is to – the first visit, 
the beginning of a treatment period or the next visit (it would make no sense to record 
queuing times for the next visit since it isn‟t really that, it is just the time until the next agreed 
visit). An analysis like this (the quality of data recording and hence internal reporting) is not a 
primary target of the current study, since it is not actually applicable to the current treatment 
system. However the above general overview suggests that this sort of data is irrelevant 
and/or poorly recorded. In either case, it cannot be used to gauge the quality of recording and 
internal reporting. 
Yet, as Dr. Lauharanta points out based on his studies of the implementation of packaging in 
somatics, the quality of data recording and thus that of internal reporting increase with the 
introduction of a packaging system such as the DRG. One might thus argue that the quality of 
this data is likely to increase, if the proposed changes were to be implemented. In addition, it 
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should be noted, that the presence of these variables in the database once again suggests that 
treatment packages can be recorded. Although currently only used in somatics, the platform 
for recording and analysing treatment packages also exists for psychiatry. 
  
Data Irrelevant for the Study 
The raw data table included plenty of information that was of no use for the analysis 
conducted further. These included several indexing variables (such as record ID, episode ID), 
some technical variables that were also included in other variable (such as “day of visit”, 
“month of visit”, “year of visit” vs. “date of visit”), a large number of completely irrelevant 
fields (such as “hour of visit”; i.e. the time on the clock when the patient came in, “age 
group”, “procedure code”, “municipality to be billed”), and finally one that was not part of the 
target of the study (diagnosis of F33, rather than F32). The irrelevant or redundant data made 
the worksheet unworkable and did not contribute to the final analysis. For example, “type of 
visit” could have been very valuable, but it was inconsistent and the type of visit could also be 
derived from the “cost of visit” by examining the price list of visits. Some data was thus 
combined and some was discarded. What was left then was a refined version of the data that 
included just the information vital for the analysis conducted.  
 
Refined Data 
The data was divided into three separate worksheets: all visits, patients with more than one 
visits, patients with a single visit with 134476, 10275 and 3310 rows respectively. This 
division was done to simplify the sorting, the querying and the analyses that would be 
performed. The data was sorted, calculated and reformatted using MS Excel. This was 
because Excel is easy to use and it has the necessary functions. The following paragraphs 
describe the data fields and their applicability to various analyses.  
 
Indexing Variables 
The primary indexing variable of the data is “Patient ID”. This is a unique code assigned to 
each patient in Ecomed. Although patient ID is unique to each patient, it is repeated for each 
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visit that a given patient has had at HUS. Indexing by this variable would allow an analysis of 
both single visits as well as single patients. The visits on the other hand are indexed simply by 
the automatic indexing table generated by the statistical software ; they hence range from 1 to 
134476 on the “visits” sheet. 
 
Variables in the Data 
A number of important descriptive variables were readily available in the data sheets provided 
by Datawell. These are “cost1”, “product”, “totcost”, “date of visit start”, “date of visit end”, 
“type of visit”, “product class”, “duration of visit”, “diagnosis”, “place of treatment” and 
“gender”. Cost1 is the cost of a visit. It should ideally be determined by the price list of HUS, 
and vary depending on the product. The product variable is a code such as 7401 (“other visit”) 
or 7201 (“first visit”), which corresponds to the visit to the product to be billed. 
Unfortunately, over 80% of all products were “other visits” which presented a problem in the 
later analysis. Totcost is the cost of the visit itself plus any procedures performed. This could 
give an insight into cost variances (later discovered to be inapplicable since the majority of 
totcosts were identical to cost1).  
The date of visit variables are central in the later use as reference point for both time 
progression analyses as well as derivations for treatment period lengths and frequencies. For 
outpatients the two dates would equal (since an outpatient leaves the clinic the same day he 
arrives). The type of visit (outpatient or inpatient) variable is just another classification that 
could explain differences in pricing or reveal patterns in treatment methods (later found to be 
unusable since 98.8% of all visit types were outpatient visits – this would also be redundant 
since “duration of visit” would tell the same thing). The product class shows whether the visit 
is billed by DRG or with other methods. This variable was left just to confirm that DRG is 
indeed not used in psychiatry (despite the fact that a column for DRG does exist, and has been 
diligently filled with one DRG code) – 98.8% of all visits are “non-DRG” based. 
The diagnosis variable would be central in further analyses, since one of the questions for this 
study is “how do treatment methods differ for different diagnoses”. As mentioned before, the 
data for F33 (recurrent repressive episode) were dropped from the sample. The ones left 
would hopefully turned out to demonstrate different treatment methods and hence conclusions 
could be drawn for each individual diagnosis, and some variance in the data could be 
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explained by the diagnosis group that an observation belongs to. Unfortunately this data had a 
lot of different formats (e.g. F32.2 would be written as F32.2, F32.20, „   F32.2) and would 
hence result in odd statistics – it had to be corrected by means of a strenuous formatting and 
testing on constantly jamming  hardware. Of equal importance as a classification variable was 
the place of visit. These were found as codes for individual clinics in the data. Separate clinics 
belong to greater entities that are the Jorvi and Peijas hospitals. These observations thus had 
to be refined from “clinic x,y,z” into “Peijas” or “Jorvi”. Finally, the gender variable was also 
available in the data. This was expected to be of minor importance in further analyses but was 
kept just in case – for the sake of curiosity sake. 
A summary of some visit variables that were kept of the original data (in the “visits” sheet): 
Item Count % of total 
Place 
Jorvi 74363 55.3 
Peijas 60104 44.7 
Year of visit 
2004 25793 19.2 
2005 24487 18.2 
2006 23974 17.8 
2007 21194 15.8 
2008 20469 15.2 
2009 18550 13.8 
Diagnosis 
F32.0 6009 4.47 
F32.1 53887 40.07 
F32.2 42714 31.77 
F32.3 9653 7.18 
F32.8 1360 1.01 
F32.9 20844 15.50 
Gender 
Male 44911 33.4 
Female 89556 66.6 
 
Derived Variables 
There was a number of variables that were not readily available in the data but had to be 
derived for further analysis. Essentially, everything that had to do with the “per-patient” 
approach had to be calculated since the data is Ecomed is on the “per visit” basis. These, and 
several others that seemed necessary for future analyses, are: “Duration of treatment”, 
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“Duration of visit”, “Number of visits”, “Frequency of visits”,  “Total cost” and “Month of 
visit”. 
Duration of treatment is one of the central variables used in further analyses. It is simply the 
period (in days) between the first and the last visit for a given patient ID. The dates of visits 
are documented well and thus this variable has a high degree of consistency. Yet although it 
used to draw out some conclusions in the further analysis, this variable is subject to two major 
errors: the bias towards short durations (as explained before) and a number of seemingly very 
long durations, caused by the fact that separate depressive episodes do not have separate 
markers. A patient with two visits three years apart clearly has separate episodes, not two 
infrequent visits in a single episode. In addition, there was a separate column for the duration 
of visits in the “visits” sheet that would allow us to see the duration of treatment up to a given 
point. For the last visit this would equal the total duration, for the first visit it would be zero, 
and for others it would be somewhere in between. Finally, the month of visit column on the 
visits sheet is simply shows the duration of treatment in months. This was included to ease the 
processing load on the statistical software (it would classify the durations in months rather 
that in days). 
The duration of visit is the time between the start of a visits and its end. For outpatient visits 
this variable would always be 0. Although outpatients would be in a central role in this study, 
the variable was still kept just in case. When this variable was calculated, it revealed an error 
in the recording process. There were several (15 or so) visits that did not have an ending date. 
This caused Excel to read the missing date as 01/01/1900 resulting in treatment periods of -
40,000+ days. To correct this error, it was necessary to go back to the raw data and pick out 
the finishing date by the “number of inpatient care days” column. In addition to the single 
visit lengths, a cumulative per-patient length of visits was calculated. This would make 
further classification possible by allowing a division of the patients into those with inpatient 
care stays and to those without. 
The number of visits and the total cost are somewhat self explanatory. These are just the 
summed costs and visit tallies per patient. Here it should be pointed out that “Total cost” and 
“Totcost” are different variables. The former is a derived variable – the sum of all costs per 
patient, whereas the latter is the raw variable from Ecomed – the total cost per visit. The 
number of visits, as the duration of treatment would also have a separate “up to” column in 
the visits sheet, where the number of visits would accumulate to the overall sum with time.  
42 
 
Data Analysis 
This chapter goes through the process of data analysis and summarizes certain central 
findings. The analyses were mostly conducted using Minitab statistical software originally 
developed in Pennsylvania State University. The reason this software was selected is that a 
copy was already available. The majority of the following analyses only consider patients 
with more than one visit, and those with no inpatient care stays. The other two groups will be 
covered in less detail in the final subchapters since that analysis is not applicable to the 
patterns identified elsewhere in the analysis. As said before, the aim of this study is to find 
patterns in treatment methods, and patients with a single visit or inpatient care stays comprise 
a separate subgroup or fall into a different classification technique respectively (by diagnosis, 
by type of visits, by place of treatment etc.). It should also be once again noted, that all of the 
data is biased towards shorter treatment periods (and lower costs and fewer visits than in 
reality) due to the sampling method described in the previous chapter. Findings of this chapter 
would hopefully enable the formation of some key conclusions that would then be tied to 
practice in the final chapters.  
The first subchapter analyses the formation of costs in the sample and summarizes the 
findings. The second subchapter deals with the arrangement of frequencies of visits, the third 
subchapter summarized the question of outpatient care and inpatient care, while the fourth 
subchapter analyses the durations of treatment and identifies the patterns found therein.  
 
Cost  per visit 
The cost per visit is ought to be determined by the product of the visit. Product prices are 
assigned for every year according to the below classification and the place of treatment (the 
price list for 2010 can be found in the appendices). The possible categories are: 
Code  Product 
270 A day of psychiatric treatment, i.e. inpatient care 
6101 Emergency visit - “Päivystyskäynti” 
7201 First visit 
7401 Other visit 
7501 A daytime visit – “päiväsairaanhoitokäynti”  
7601 Rehabilitation visit 
7701 Phone call / letter 
7801 Consultation 
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As mentioned before, the vast majority (over 80%) of visits were “other visits”. However, the 
data showed that there were several different costs for product 7401. For the following 
analyses only data for 7401 will be considered to limit the amount of variance (this only 
includes outpatient visits). This begs the question: what determines the difference? The price 
list specifies a particular price for every clinic. Since the distinction into clinics was removed 
in the data refinement process one cannot confirm that the differences in cost stem from this 
fact. Just to make sure, a histogram was plotted to show that costs did vary within place of 
treatment (as in Jorvi vs. Peijas, not the separate clinics), but did not depend on them: 
 
Figure 9 There is signification variability in visiting costs for each hospital 
Since the place of visit did not appear to be the distinct determinant of cost classes, the 
possibility of grouping by the year of a visit was considered. After all, the price list is 
compiled for every year and is hence subject to changes. A scatter plot of cost vs. date of visit 
reveals that there are indeed distinct levels of costs for every year:  
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Figure 10 The costs per visit vary greatly over time 
The HUS price list has a number of different costs for different clinics and there is reference 
to something called the price group. The data for the costs of past years is not readily 
available, so what follows is an attempt to determine them from past data by splitting the 
observations into years and identify the major cost groups. Below is a marginal plot depicting 
the costs of a visit for year 2004:
 
Figure 11 In 2004 there were two major and one minor cost classes 
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This showed that for the year 2004, there were two distinct groups of visit costs: 120€ and 
110€. Also there was a minor number of visits worth 160€, this class is further referred to as 
an outlier (it might have been a cost for a small clinic that was later integrated into a bigger 
hospital and hence has its own cost). In a similar manner, this analysis was conducted for all 
the following years and the results were (the minor variances are dismissed as rounding 
errors): 
Year Cost 1 Cost 2 Outlier 1 Outlier 2 
2004 110 120 160  
2005 110 140 160  
2006 150 190   
2007 143, 145    
2008 143, 145, 148, 149  178  
2009 154, 155 184, 186, 187  208 
 
In the above table costs 1 and 2 accounted for well over 95% of all visit costs, while being of 
comparable size with respect to each other. Since the division was this considerable (albeit 
crude – it makes the assumption that Cost X in a given year corresponds to Cost X in 
another), it would be interesting to see whether the cost class of visits would change over the 
treatment period. A histogram of cost classes over time showed that the grouping seems valid, 
with the exceptions of years 2007 and 2008, when Cost 2 didn‟t exist.  
An analysis of visit cost classes versus visiting month yielded the following results, presented 
below in graphical form:
 
Figure 12 The proportions of the two cost classes are very similar 
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There seems to be no major differences in cost classes over the duration of treatment. The 
only notable difference is the fact that after 12 months of treatment, the expensive visits 
(CC2) end, and patients are mostly treated at the cheaper visits. It is difficult to say whether 
this difference is significant, yet it cannot be considered a coincidence. This analysis allows 
us to draw out several conclusions: 
- costs per visit are the main determinant of total costs (with phone calls, letters 
and consults only comprising 2.1% of total services) 
- treatment in cheap clinics lasts slightly longer than in the expensive ones  
- the proportional amounts of cheap and expensive visits vary in the same way 
for each diagnosis 
- the cost class suggests a given procedure to a slight degree 
- the notch in CC2 at 12 months suggests that that particular type of treatment is 
virtually dismissed at that stage 
These findings, although not very decisive, do show some grouping which can be later used to 
assess the possibility of splitting patients into groups. The degree of grouping will be later 
analyzed with references to the professional opinion of a panel of HUS doctors. The major 
cost classes found above will also be later used as benchmarks to draw out ideal scenarios 
with standardized +-costs. 
 
Total cost and number of visits 
 “Total cost” is the variable that shows the total cost of a treatment of a patient. “Number of 
visits” on the other hand shows the total number of times a patient has visited a clinic during 
his treatment. As billing is done on a per-visit basis, the total cost is expected to be linearly 
dependent on the number of visits. Essentially, a high degree of linearity would suggest a low 
importance of the actual cost per visit. The following scatter plot shows just that: 
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Figure 13The linear relationship between total cost and the number of visits 
The line of best fit shows that the average cost per visit in Jorvi is 149€, whereas in Peijas it is 
151€. The lines are linear which shows that the total cost is indeed determined by the number 
of visits. Assuming the cot per visit should ideally be always the same, for further calculations 
in this study the number of visits can be considered equivalent to the total cost. It should be 
noted however, that the variance in total costs is quite significant, with the gradients of most 
expensive vs. the least expensive visits in the above graphs ranging from 190€ per visit to 
110€ per visit. The issue behind a cost of per visit is thus in practice of vital importance for 
the total cost of a patient‟s treatment. 
At this stage the distribution of observations should also be noted. They carry no implications 
to the analyses of this study, but they might be of general interest. Below is a histogram of the 
number of visits to each hospital arranged by years: 
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Figure 14 The number of visits to Jorvi has been decreaseing but has remained fairly level in Peijas 
Two facts strike out from this graph: the number of visits to Jorvi is declining while 
remaining level in Peijas. The reason for the decline in number of Jorvi is likely to have an 
underlying cause such as restructuring of units. The number of visits to Jorvi has decreased 
from 7700 in the first half of 2004 to just 3830 visits in the start of 2009. Peijas on the other 
hand had 5200 visits 5240 visits at those times. This observation, although not serving a 
distinct purpose in the current thesis, is overall peculiar to say the least. 
What comes to the number of visits for individuals patients, they follow an exponential 
distribution (with patients with two or three visits as the exceptions). There are no apparent 
peaks or clusters of visit numbers – the distribution appears virtually continuous. This 
suggests that the treatment does not follow any guideline specifications as to the number of 
visits that a patient should have over the course of their treatment. Rather, the patients‟ 
treatment is ended at any point when their condition is considered to no longer require 
specialized healthcare (unfortunately the clinical health assessment data is insufficient so say 
whether this stage is determined by some standard, e.g. a given GAS score, or by the 
personnel‟s best judgment). The following diagram shows the distribution of the number of 
visits across different diagnoses:  
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Figure 15 The distribution of the number of visits is relatively smooth  
The number of visits follow the same distribution for each diagnosis, yet the curvature is 
rather different depending on the diagnosis – i.e. severity of the depressive episode. The 
apparent conclusion seems to be that the more severe an episode is, the greater the number of 
visits, which makes a lot of sense in practice. The peaks in the number of visits for F32.8 
seems interesting at first, but their sample consists of only 117 observations (just over a 
percent of the total) which makes them vulnerable to randomness. The means, medians and 
standard deviations of the number of visits by diagnosis group are presented below: 
Diagnosis Mean Median Standard Deviation 
F32.0 9.98 6 10.66 
F32.1 12.83 8 14.90 
F32.2 15.39 9 17.86 
F32.3 16.46 9 20.73 
F32.8 11.27 5 12.76 
F32.9 8.91 5 10.91 
 
There is no significant in difference when the different places of treatment are considered. 
With the proportion of diagnoses almost the same in each hospital (suggesting no cultural bias 
in diagnostics), the following table of means and medians for each diagnosis split according 
to the place, shows the similarities: 
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Diagnosis Jorvi (mean) Peijas (mean) Jorvi (median) Peijas (median) 
F32.0 9.91 10.07 6 7 
F32.1 12.74 12.94 8 8 
F32.2 15.58 15.16 9 9 
F32.3 16.39 16.53 9 9 
F32.8 12.97 9.49 6 4 
F32.9 8.53 9.38 5 5 
 
The above information which points out the fact that the numbers of visits for each hospital 
are very similar (a virtually identical distribution) can be further shown on a histogram of 
number of visits by place of treatment: 
 
Figure 16 The distribution of number of visits per patient is virtually identical for Peijas and Jorvi  
Finally, the number of visits (and hence ideally the total costs) of treatments were plotted on a 
cumulative density function graph to show the number of visits required to achieve a 
symptomless state for the patients. Below are two charts with reference lines drawn at 66% in 
the former and 90% in the latter (these percentages were selected randomly just to get a 
general view of the situation): 
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Figure 17 The number of visits required for remission in 66% of patients grouped by diagnosis 
 
Figure 18The number of visits required for remission in 90% of patients grouped by diagnosis  
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The above results are summarized in the following table, with additional columns added for 
theoretical standard costs: 
Diagnosis Number of visits Cost / visit = 
110€ 
Cost / visit = 
150€ 
Cost / visit = 
190€ 
66% remission 
F32.0 9.65 1061.5 1447.5 1833.5 
F32.1 13.40 1474 2010 2546 
F32.2 19.12 2103.2 2868 3632.8 
F32.3 16.40 1804 2460 3116 
F32.8 6.48 712.8 972 1231.2 
F32.9 11.14 1225.4 1671 2116.6 
90% remission 
F32.0 18.64 2050.4 2796 3541.6 
F32.1 26.38 2901.8 3957 5012.2 
F32.2 38.58 4243.8 5787 7330.2 
F32.3 32.83 3611.3 4924.5 6237.7 
F32.8 12.14 1335.4 1821 2306.6 
F32.9 21.58 2373.8 3237 4100.2 
 
The analysis of total costs and the number of visits lead to these major conclusions: 
- number of visits and total cost are directly related 
- number of visits is (almost continuously) exponentially d istributed 
- number of visits does not group observations into distinct groups (i.e. packages)  
 
Frequency of visits 
This subchapter analyses the frequency of visits by diagnosis and place of treatment. In 
addition,  it points out the time intervals at which visits are most commonly held. The 
methodology of treatment duration measurement carries an error due to the fact that a patient 
ID is carried over a number of depressive episodes (whilst not properly differentiated by the 
different diagnoses of F32 or F33). For example, a patient might come in for a visit or two in 
2004, then leave for two years, then come in again for more visits in 2007. This would result 
in an average time between visits of over 200 or 300 days. These observations are thus 
overlooked in the analysis. 
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For the reason mentioned above, considering the full range of frequencies yielded non-
interpretable results. But an adjusted sample, with frequencies at less than 90 (i.e. the longest 
duration between visits considered is 90 days) by diagnoses, looks as follows: 
 
Figure 19 Distribution of frequencies by diagnosis 
The distribution shows the most common interval between visits to be somewhere between 7 
and 14 days. The very slight differences in the shapes of distributions suggest the following: 
- patients with F32.3 and F32.8 tend to visit at erratic intervals (their distribution is 
more levelled) 
- visits of patients with “simple diagnoses” of F32.0, F32.1 and F32.2 tend to be more 
clustered around 7-14 days 
- differences in distributions are quite similar to each other and thus little can be said 
about the implications 
However, a much more interesting plot is not that of the aggregate frequency, but rather of the 
frequency up to a given point in treatment. In other words how often do patients of given 
diagnosis groups visit the clinic during their first month, the first two months, and the first 
three months of their treatment. This data is presented in the three histograms below: 
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Figure 20 Frequency of visits during the first month of treatment by diagnoses 
 
Figure 21 Frequency of visits during the first two months of treatment by diagnoses 
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Figure 22 Frequency of visits during the first three months of treatment by diagnoses 
A point of note in the above graphs is that the distribution appears somewhat smooth due to 
the fact that the frequencies are being constantly varied. For example, referring to the first 
graph: a patient would visit three times in the first week, twice in the second week, and once 
more in the third and fourth week of the first month. The average frequency for the first 
month would hence turn out to be 30 / 7 = 4.29. These observations comprise the smooth 
curve underneath the distinct peaks. The peaks on the other hand represent the patient visits 
with set visiting periods. The following table summarizes the position of the highest peak (or 
peaks where almost equal) for each period – e.g. peak at 3.5 means that a patient has had a 
visit twice a week: 
 1 Month  2 Months 3 Months Explanation 
F32.0 3.5, 7 7 7 Once a week 
F32.1 3.5, 7 7 7 Once a week 
F32.2 3.5, 7 1.5, 7 1.5, 7 1-3 times a week 
F32.3 1.5 1.5 1.5 3 times a week 
F32.8 3.5, 7 7 7 Once a week 
F32.9 3.5, 7 3.5, 7 7 1-2 times a week 
 
The above analysis shows some interesting facts of the frequencies of treatment that can be 
summed up as follows: 
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- the more severe an episode, the more variance there is in frequencies  
- the more severe an episode, the more frequent visits normally are 
- visits are more frequent at the start of treatment 
- there are distinct peaks at standard week long intervals 
It can hence be concluded that the staff‟s prudence in matters of visit frequency play a vital 
role in the treatment methods. As the CCG suggests, in cases of severe depression (especially 
with a change of self-harm), the frequency of visits is ought to be increased. However it 
should also be noted, that the frequency of visits does not tend to 1 as the period of 
observation is reduced. In other words, there does not seem to be a period at the start of 
treatment with very frequent visits where the condition of a patient would be thoroughly 
investigated (whereas this tendency was expected by the initial theoretical hypothesis). 
 
Inpatient and Outpatient care 
The difference between inpatient and outpatient care is a central question in secondary mental 
health care. Despite the fact that the number of outpatient care visits (and hence their costs) 
are somewhat equal in Peijas and Jorvi, a simple analysis of total costs shows that these 
values are quite different for the two locations. Below is a table summarizing some key total 
cost statistics by place and diagnosis: 
Diagnosis N of patients % of 
patients 
Cost / pat 
(95% sample) 
Total inpatient 
care days 
Inpatient care 
days / pat 
Jorvi 7486 100% 1407.4 13098 1.75 
F32.0 496 6.6% 896.6 250 0.50 
F32.1 2949 39.4% 1363.5 3281 1.11 
F32.2 1868 25.0% 2000.4 4983 2.67 
F32.3 438 5.9% 3083 2989 6.82 
F32.8 78 1.0% 1424 58 0.74 
F32.9 1657 22.1% 791 1537 0.93 
Peijas 6100 100% 1430 11335 1.86 
F32.0 433 7.1% 885 549 1.27 
F32.1 2282 37.4% 1384.9 2031 0.89 
F32.2 1541 25.3% 2041 4342 2.82 
F32.3 376 6.2% 3297 3283 8.73 
F32.8 78 1.28% 1044 99 1.27 
F32.9 1390 22.8% 849.1 1031 0.74 
 
The above table shows Peijas to have slightly more inpatient care days. Although perhaps 
interesting in the big picture of the progress of psychiatry, for the current study it is of little 
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applicability. This is because depression tends to have very few visits of inpatient care as 
opposed to the total sample. In the data of this study, only 1.1% of visits were of inpatient 
care. Not only does this make the results of minor significance, but suggests that the data 
might be insufficient. With a simple chart of number of inpatient care days per time, an 
enormous variance can be seen, which denies the possibility of identifying a pattern or a 
tendency: 
 
Figure 23 The number of inpatient care days in each hospital has a high variance 
 
Duration of treatment 
The duration of treatment was expect to be the central variable in determining patient groups 
and patterns in treatment. This is also the variable that is most explicitly defined in the CCG, 
who state the expected remission rates in terms of the duration of treatment, not in terms of 
the variables discussed previously. As we have seen, the number of visits is subject to change 
depending on the staff‟s perception of the severity of the condition of a patient; it is not tied to 
the effectiveness of a treatment method. In other words, remission is expected to occur after a 
given number of days of treatment (depending on the treatment used: drugs, and/or therapy), 
not after a given number of visits. The duration of treatment  is hence the most promising 
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variable for finding patterns and hence the possible future division of depression patients into 
distinct groups. Theoretically, there should be distinct peaks at times when treatment has been 
effective for a significant proportion of the sample. The peaks would be but means of 
distributions around whom the probable observations should be arranged (since e.g. drug 
treatment does not have an effect at exactly 60 days for everyone). Below is a histogram of 
treatment durations: 
 
Figure 24 Duration of treatment for all diagnoses and both hospitals 
The graph shows a crude division into groups as follows: 
- up to 60 days (2 months) 
- up to 300 days (10 months) 
- up to 1110 days  (3 years) 
- 0 days, a group of patients with only 1 visit are excluded from the above graph 
The graph also shows a number of observations at over 1500 days. Those will be from now on 
discarded as either outliers or erroneous observations (due to the way in which durations were 
calculated: time from first to last visit). Also, it should be noted again, that the observations 
are biased towards the shorter ones. This means that the skew of true duration treatments 
would be more gradual. 
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When split into places of treatment, the same graph looks as follows: 
 
Figure 25 Durations of treatment split by place of treatment shows minor differences 
Although the shapes are somewhat similar, peaks at 24, 28 and 32 weeks seem to be 
distinctive for Jorvi, and clusters of peaks at 12-18 and 22-28 weeks for Peijas. Although 
unlikely, this could mean that thanks to a difference in treatment methods, patients respond to 
treatment at those particular stages. It is more likely however, that the evaluation of treatment 
culture is different in the two hospitals. i.e. Jorvi evaluates (and aims to end treatment) the 
patients at 4 week intervals whereas Peijas does so more regularly. The most likely 
explanation is however coincidence.  
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When the same graph is plotted while divided by diagnoses, the groups become even more 
apparent still: 
 
Figure 26 The duration of treatment by diagnosis shows a distinct pattern  
There are some differences in durations by diagnosis. Again, the more severe the episode, the 
longer the duration is likely to be. The shape of the distributions can be summarized as 
follows: 
- a distinct peak at 14-30 days (peak1) 
- a distinct peak at 330-350 days (peak2) 
- decrease in frequency during 30-200 days (decrease1) 
- increase in frequency for 200-350 days (decrease2) 
- a sharp drop in frequency after 350 days (drop1) 
- a plateau of durations for 350-1100 days (plateau1) 
Unfortunately there is no readily available data to explain the underlying reason for these 
groups. Although the patterns do alter by diagnosis, that is by no means the determining 
factor. It can be also seen that the place of treatment was not the reason either. It has also been 
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shown before that the frequency of visits does not appear to be divided into groups. The fact 
that frequency is not grouped but durations are, suggests that frequency is not likely to be the 
factor in the durations of treatments either. Finally, gender nor age appeared to have a 
connection to the duration. 
According to the CCG there are essentially two types of effective treatment: drugs or therapy 
(or their combination). If this data was available for the study, the following scenario (the 
actual underlying reasons might be different) for an apparent explanation for this shape could 
be claimed with more certainty: 
- a group of patients only undergoes assessment or a short intervention and then leaves 
the system (peak1) 
- for another group of people drug and therapy treatment: whether effective or not, they 
are removed from the system (peak2) 
- a group of patients is kept on for follow-up or other treatment attempts (plateau1) 
Since the underlying reason cannot be determined by the data, a proper distinction of 
distributions cannot be drawn either. If this was not the case however, the distributions could 
well look like this:
 
Figure 27A possible group of distributions by treatment method (e.g. short treatment or assessment, therapy + drugs)  
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The above graph is not to scale, it simply illustrates the idea of several distributions (with 
distinct underlying reasons, such as treatment methods) comprising a total that resembles the 
graph from before. The shaded region at 0 represents that negative treatment durations and the 
shaded region on the right represents the sudden drop in durations at approx. 350 days.  
The distinct notch at 350 days strongly suggests an adherence of treatment culture to the idea 
that treatment beyond that point is essentially inefficient according to the CCG. Patients thus 
tend to be discarded from the system after that point. However it should be noted that some 
13% of all patients do carry treatment for over 350 days. This on the other hand corresponds 
to just over 28% of the total costs for the patients with more than 1 visit. It should also be said 
that the plateau does not consist of patients with rare visits, as seen on the fo llowing marginal 
plot: 
 
Figure 28 The plateau patients consist mostly of those visiting at least once a month 
The above analyses do carry two known (but indistinguishable) errors: the aforementioned 
bias towards short periods and patients who did not finish the treatment plan. If the bias was 
corrected, the durations from the early peaks would be redistributed along the graph towards 
the longer ones. The patients who ended their treatment on the other hand create noise for the 
distribution. It is impossible to determine their proportion but they are likely to be somewhat 
evenly distributed along the histogram. If they were accounted for, the peaks in the 
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distributions would become proportionally greater and hence even more apparent. In other 
words, these two error factors distort the data to make the conclusions less apparent. But since 
it is known that they exist, it could be claimed that the real distinction of patient groups is 
even more significant and apparent. In other words, the groups are “at least this distinct” (as 
visible on the above graphs). 
Despite the absence of the concept of a treatment package in outpatient care in psychiatry, the 
investigation of durations of treatments appears to suggest that there are still quite distinct 
groups in terms of durations. What the underlying reasons are, is difficult to say without 
additional data. It can also be said that there is a degree of adherence to the CCG. Rather, it 
can be said that the CCG holds in practice. In other words, it is unknown whether the groups 
exist due to the staff‟s attempts to follow the CCG, or the CCG is based on similar empirical 
evidence that follows distributions as above.  
 
Discussion of Findings 
The study aims at identifying treatment patterns in the outpatient care of depression at HUS. 
The critical variable that appeared to reveal patient groups was found to be the duration of 
treatment. Although the underlying cause of the groups was not apparent from the data used, 
the likely causes seem to correlate with the CCG to a significant degree. The visiting costs, 
the number of visits and the frequencies on the other hand showed a continuous distribution 
thus exhibiting no grouping and thus do not serve the immediate aim of the study but 
contribute to the general understanding of the field. This final chapter goes through the 
findings – first those that turned out to answer some questions posed by the aims, and then 
those that are interesting for the understanding of the big picture. 
 
Patient groups – theory and practice 
The most important finding of the study is the identification of patient groups by the duration 
of treatment. Although the data is distorted the patterns of treatment duration are apparent. In 
addition to patient groups being distinctly visible, they can be tied to the theoretical treatment 
framework that is the CCG. The groups of the 12332 (those who only had outpatient care) 
patients who were considered in the analysis t can be summarized as follows: 
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- Patients with a single visit 
- Patients with duration of 0-30 days 
- Patients with duration of 330-350 days 
- Patients with duration 350-1100 days 
 
Figure 29 Grouping was apparent in the durations of treatment by diagnosis 
If underlying reasons were found in further studies, and if they would confirm the assumption 
that the apparent division into groups is caused by treatment methods, the grouping could be 
something like this: 
Group 1: “A single visit to a psychiatrist for evaluation” 
Group 2: “A short drug treatment of depression” 
Group 3: “A long treatment of depression with drugs and therapy” 
Group 4 should be excluded from treatment as the CCG suggests it is ineffective  
The average costs for these groups would then be counted and patients billed accordingly, as 
their treatment progresses to the following stage. Determining the shapes of the curves and 
thus the averages poses a problem at the moment, since the data did not include information 
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of treatment type. An attempt to figure out the treatment type based on cost levels pro ved 
unfruitful. This is thus left for future studies of the topic.  
The number of patients with a single visit comprise a significant proportion of the sample. 
With 3310 observations, their share of the total is 26.8%. This is by far the greatest individual 
group in the sample. In terms of the CCG and the “general consensus” framework they are 
those who entered the system for an initial visit and were deemed not suiting for the 
secondary health care of depression. The reasons for this decision include anothe r diagnosis 
or a mild case of depression. 
The proportional size of the other peaks is a lot less precise, in fact it is somewhat speculative. 
Nonetheless, if the assumption of a fit of two cut (as explained above) normal distributions 
holds, they would equal the area under the curves of the distributions where each curve would 
correspond to a particular method of treatment: 
 
Figure 30 A possible fit of two normal distributions 
However, based on the data available to this study it is all but impossible to even make 
estimates of these areas. This is due to the two errors that have been discussed at length 
before, as well as to the actual causes (since treatment type data was not available) of the 
distributions. In a graphical representations the two errors can be shown as follows: 
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Figure 31 The two major errors in the data  
 
Packaging has been seen to increase motivation, efficiency and data quality. In terms of the 
durations, there should be two significant benefits: degree of number of drop outs should 
decrease since patients would be motivated to stay for the whole paid duration (the peaks in 
the distribution would be steeper, while the plateau between them would be shallower) and 
the excessively long treatment periods would decrease (the long tail after 350 days) since the 
maximum duration package would abide the CCG. 
The reduction of drop outs (i.e. the increase of completed treatment periods) would likely 
improve the overall output of mental health care in terms of clinical metrics. This is due to the 
fact (as strongly suggested by the CCG) that a completed treatment period is significantly 
more effective at treating the depressive episode and preventing its reoccurrence.  
The reduction of the patients in the tail of the distribution is particularly significant in terms of 
cost savings. The cumulative total cost for patients with more than one visit is €16,945,000. 
The cost of those with less than 360 days of treatment is €11,982,000. This means that the 
patients in excessive care account for some 29,4% of cumulative costs while comprising only 
13% of the sample. The following histogram shows the cumulative costs, where the notch at 
360 days is clearly visible: 
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Figure 32 The cumulative costs of outpatient visits in terms of duration of treatment  
 
It is naïve to assume that the introduction of packaging would completely eliminate treatment 
durations of over 360 days; it might be both impractical or even harmful to the patients. 
However it would certainly affect this tendency to some degree as patients would be treated 
for more than 360 days only in exceptions. These exceptions would be the cases when a 
doctor strongly believes that something can still be done for the patient in secondary health 
care, although the CCG suggest otherwise. Even so, these cases would be billed according to 
the traditional method, not by the packaged prices, as they would outliers in the analysis of 
the mean cost. 
 
Summary of practical findings 
Data analysis and the assessment of its quality reveal a number of interesting and practical 
findings that turned out to be curiosities rather than serve the final aim of this study. These 
include facts about the database, the quality of records, tendencies in total costs and visits as 
well as frequencies of visits.  
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The overall quality of the database is rather deficient. This can be explained by the major fact 
that the database is generally meant for other treatment cultures (i.e. one with packaging, as 
successfully done in somatics) and the lack of recording incentives in the current culture. As 
said, treatment packages do not exist in psychiatry. Therefore the fields that refer to 
packaging factors are not actually even meant to be filled in. For example, since there is no 
such thing “a treatment package for F32.1 depression with drugs”, there is no reason to mark 
a patient‟s first visit as the first visit – it would not serve any purpose for billing, treatment 
planning or quality analysis. However, if packaging was implemented in psychiatry, it would 
create this incentive making quality and efficiency analyses (and hence internal reporting) a 
lot easier. This culture has been implemented in somatics and the results have been 
tremendous – quality of records has increased steadily. 
Total cost and the number of visits appear to have no grouping qualities. The distribution of 
each showed a continuous distribution which suggest they are not bound to a specific patient 
type or treatment method. However, they did prove the somewhat apparent assumption that 
more severe diagnoses require more visits (and hence cost more). It was also shown that these 
variables exhibit linear dependency and are thus virtually equivalent. There is however 
considerable variations in visit costs, even though they are ought to be standardized by visit 
type. The quality of records for visit types appears to be deficient; over 80% of all visits are 
“other visits”. This makes classification and quality analysis challenging to say the least. To 
counter this apparent flaw, an attempt was made to classify visits by their cost groups. 
Although the grouping worked (the levels of cost groups were quite uniform), this turned out 
not to be useful in finding patterns in treatment. In other words, although the idea of cost 
classes worked, the classes turned out to be arbitrary and not bound to a treatment method.  
Another interesting finding in the analysis of the number of visits was the fact that overall 
they have decreased in Jorvi while remaining somewhat level in Peijas. This is very surprising 
considering the fact that Jorvi is responsible for the treatment of about one and a half times 
the population of Peijas. There must be an underlying reason for this finding, but finding it is 
omitted in this paper as it is of little significance to the aim. The distributions of the number 
of visits per patients were very similar if not identical. This suggests that there is no 
considerable difference in treatment cultures between the two in terms of the number (nor 
frequency) of visits. 
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The analysis of frequencies of visits for different time periods and diagnoses showed some 
interesting facts. Firstly, the frequencies again depend on the severity of the condition; the 
more severe, the more frequent the visits. Secondly, although there is a smooth component to 
the frequency distribution (i.e. periods between visits vary), there is also a significant degree 
of adherence to the calendar. In other words visits once a week are significantly more likely 
than once in 6 days. This is natural for practical reasons but might to some degree interfere 
with optimal treatment. Thirdly, the frequency of visits does decrease as time passes. i.e. 
visits are more frequent in the first month than during the first two or three months. Finally 
however, the decree of change from frequent to rare visits is not quite as dramatic as 
expected. This is by no means a bad tendency – rather it is just an observation. The fact that 
the visits are not quite as frequent at first does not meant they are insuffic ient (or poorly 
scheduled). Instead it shows that they are just not that necessary. This is idea is further 
supported by the fact that initial visits for F32.3 (a severe condition) are very frequent indeed: 
when needed, visits are frequent.  
The above observations suggest that the staff‟s prudence and qualification play the central 
role in treatment processes. For severe cases the frequencies and number of visits are high 
(and lower for milder cases) – whether in Peijas or in Jorvi.  
 
Conclusion 
Treatment method packaging has been shown to improve motivation and efficiency in other 
fields of medicine. This study aimed to find patterns in the treatment of depression to 
ultimately assist the implementation of packaging in psychiatry. The initial assumption of 
patterns existing was based on an official theoretical framework called the Current Care 
Guidelines, as well as an interview of several HUS managers. According to those sources, the 
grouping should be caused by the different methods that are employed in the treatment of 
depression (drugs, therapy, or both). At first however it was unclear where to look for these 
groups, so several variables were investigated.  
The data available for the study included information about dates of visits, their costs, the 
place of treatment and the diagnosis of the patients. The treatment methods were not known, 
while they were likely to be the most significant grouping variables. An attempt was thus 
made to divide the visits into groups according to cost classes. Unfortunately this did not 
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show significant grouping. However, it was shown, that there is an inexplicable variance in 
the visiting costs although they are ought to be somewhat uniform.  
Other variables that were investigated were the frequency and the number of visits per patient. 
The number of visits showed a smooth distributions with no remarkable grouping. However, 
the shapes of the distributions differed depending on the diagnosis, i.e. the severity of the 
episode. The same applied for the frequencies: the more severe an episode, the greater the 
number and the frequency of visits. This was in line with the CCG who state that the visits 
should be more frequent if the severity of the condition requires that. The number of visits 
were then fitted into a probability plot which allowed a construction of a table of cost 
estimates for given remission percentages, to give the client an idea of the distribution of costs 
for each diagnosis group. Additional analyses including the significance of inpatient care 
were conducted at the request of the client, but they showed no remarkable results in terms of 
the aim of this study. 
The variable that finally revealed patterns was the duration of treatment. The analysis showed 
a number of distinct peaks in the distribution of durations. Although with the current data it 
was impossible to say with certainty what the underlying cause was (since treatment methods 
were unknown), but the pattern seemed to fit the CCG. In fact, this study provides a valuable 
real life look at the theory of the CCG which is mostly based on controlled studies. If the 
patterns seen in the distribution were indeed caused by the different treatment types, the 
patients could be split into groups based on those types, averages for them calculated, and 
hence treatment packages created. 
Although no precise values for the sizes of the groups were found, conclusions were still 
made that support the initial hypothesis of distinct groups being found in the durations of 
treatment. The confirmation of the theory on practice allows further steps in treatment 
packaging to be made. Now that it has been shown that treatment periods exhibit grouping, 
with additional studies (namely with some that would explain the underlying causes and 
excluding the error factors), a packaging framework could be established. 
If packaging would in fact progress, a great deal of advances are expected to take place. As 
experience in somatics suggests, the quality of records, the quality of internal reporting and 
the overall efficiency would grow significantly – the implementation of the new culture could 
very well be the next big step in the modernization of mental healthcare in Finland, and thus 
the promotion of national mental health.  
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